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Abstract 
Melanoma is one of the most aggressive and inherently resistant cancers and the most 
dangerous skin cancer. While it accounts for fewer than 5% of skin cancer cases, 80% of skin 
cancer related deaths are attributed to melanoma. While resection remains the gold standard 
for melanoma treatment, surgery is only effective in providing local control of the disease if 
the cancer is detected in the early stages. Once melanoma enters the later stages, and 
particularly in the metastatic phase, recurrence is probable, and no adequate treatment exists. 
Previous work in this group has shown that photodynamic therapy (PDT) presents an 
opportunity to induce cell death in melanoma cells through the production of ROS and singlet 
oxygen at doses high enough to overwhelm the resistance mechanisms of the cancer. 
 
In this study, we investigated the use of recombinant SNAP-tag-based antibody fusion 
proteins as a means of delivering phototoxic molecules directly to cancer cells expressing the 
CSPG4 and PD-L1 cell surface receptors. SNAP-tag is an engineered version of the human DNA 
repair enzyme O6-alkylguanine-DNA alkyltransferase. It reacts autocatalytically and in a 
strictly 1:1 coupling chemistry with substrates that have been modified with benzylguanine 
(BG). Through genetic fusion of this self-labelling protein with a tumour targeting antibody, 
we developed a recombinant immunoconjugate able to carry BG-modified photosensitizers 
to selectively target and eliminate malignant melanoma cells.  
 
Conjugation of the SNAP-tag fusion protein with the fluorescent dye Alex Fluor 488 showed 
that anti-CSPG4-SNAP binds specifically to melanoma cells expressing the CSPG4 surface 
antigen. Binding was tested across a range of cell lines presenting melanoma in its radial and 
vertical growth phases, in the metastatic growth phase, in its chemoresistant form, and in 
both its pigmented and unpigmented forms. This binding data thus confirms CSPG4 as a 
suitable targeted for this treatment strategy. Conjugation of the fusion protein with the BG-
modified photosensitizer IRDye 700DX (IR700) has produced no phototoxicity as of yet. In 
light of the convincing binding analysis, it is concluded that inefficient solubilization of the 
lyophilized product resulted in inadequate conjugation of BG-IR700 with SNAP-tag. 
Nonetheless, steps have been planned to resolve the problem in future ongoing work on this 
project, and we remain confident in the applicability of this technology. The results for the 
PD-L1 fusion protein were inconclusive. 
 
In summary, SNAP-tag technology offers a simple and efficient method for 
immunofluorescent detection of cancerous cells. These fusions proteins are versatile as they 
1) can contain any antibody targeting a tumour-associated or tumour-specific antigen of 
choice and 2) can be endowed with a wide variety of substrates, as long as the latter 
contains the BG moiety.   
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1. Literature Review 
 
1.1 MELANOMA 
1.1.1 Development, characteristics and prevalence 
Melanocytes are the cells found in the epidermis of the skin that are responsible for the 
production of melanin; a pigment that carries photoprotective properties against harmful 
ultraviolet radiation (UVR) in its black/brown form, although it offers little photoprotection in 
its red/yellow form. Black/brown melanin is produced within the melanosomes and is able to 
scatter and absorb UVR, providing the cellular DNA with protection against UVR-induced 
damage.(1) Melanoma arises from the malignant transformation of melanocytes due to 
environmental changes, such as UVR over-exposure, and/or gene mutations, the most 
common occurring in BRAFV600E and N-RAS.(2) These mutations develop due to abnormal 
activation of the mitogen-activated protein kinase (MAP-K) pathway, which leads to increased 
cell proliferation and the formation of the nevi. Cells then undergo immortalisation, 
accompanied by further proliferation in the radial growth phase (RGP). Migration pathways 
are activated, and cells undergo invasion and epithelial-to-mesenchymal transition (EMT) in 
the vertical growth phase (VGP). Finally, metastasis and angiogenesis occur in the metastatic 
phase (Figure 1).(3) 
Melanoma is one of the most aggressive and inherently resistant cancers, and the most 
dangerous skin cancer. While it accounts for fewer than 5% of skin cancer cases, 80% of skin 
cancer related deaths are attributed to melanoma.(1, 3, 4) Melanoma threatens a 1 in 266 
lifetime risk in South Africa (CANSA National Cancer Registry, 2013), second only to that of 
Australia, where 1 in 17 people are estimated to be diagnosed with melanoma by the age of 
85 (Cancer Australia, 2017). CANSA reports show that South Africa has around 20 000 new 
melanoma cases annually. While resection remains the gold standard for melanoma 
treatment, surgery is only effective in providing local control of the disease if the cancer is 
detected in the early stages. Once melanoma enters the later stages, and particularly the 
metastatic phase, recurrence is probable and no adequate treatment exists.(5)  
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Figure 1: Progression of melanoma. A) Healthy melanocyte undergoes an activating BRAF mutation, resulting in 
proliferation to form a nevus. B) Subsequent gene dysregulation, immortalization of cells and entry into RGP. C) Cells begin 
invasion in VGP, as E-cadherin is lost, EMT occurs and cells move across the basal membrane into the dermis. D) 
Angiogenesis and metastasis occur in the metastatic phase.(1) EMT, epithelial-mesenchymal transition. 
 
1.1.2 Chemoresistance 
Recent years have seen tremendous advances in cancer research, which have vastly improved 
our understanding of the disease and brought about the development of new generations of 
immunotherapies and targeted therapies. Nevertheless, the majority of recent cancer clinical 
trials have not resulted in any drastic differences in treatment outcomes.(6, 7) Furthermore, 
the number of existing FDA-approved drugs, such as Vemurafenib and Ipilimumab,(8, 9) as well 
as the rate of new drug approval, is very low.(10) Despite progress in cancer research, our 
ability to reduce tumourigenicity and eradicate cancerous cells remains inadequate and most 
drugs exhibit non-specific cytotoxicity.(11) Therapeutic approaches ranging from 
chemotherapy to targeted molecule inhibition have not had the expected success,(12) as 
melanoma cells are highly successful at resisting treatment-induced apoptotic signals and are 
thus able to evade cell death.(13)  
One mechanism through which melanoma cells are able to avoid chemo-induced cell death 
is through the expression of ATP-Binding Cassette (ABC) transporters. These proteins 
A B C D 
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facilitate resistance to classic chemotherapies by causing an efflux of cytotoxins from the cells 
thus preventing the accumulation of drugs intracellularly.(4, 14-18) The ABCB5 transporter has 
specifically been shown to mediate multi-drug resistance in melanoma.(18) Another survival 
mechanism of a transformed melanocyte is its antioxidant properties. Because cancer cells 
themselves produce reactive oxygen species (ROS) and are therefore inherently exposed to 
significant oxidative stress conditions, they have a highly developed antioxidant system. The 
antioxidant system of melanoma is particularly advanced as these cells naturally contain 
antioxidant substances, such as glutathione peroxidases, catalase, superoxide dismutases, 
tocopherol and glutathione, which offer defence additional against free radicals.(19) 
Melanoma has been shown to have higher antioxidant levels than other skin cancers, making 
it highly tolerant to oxidative stress. Melanin derivatives act as potent oxidants, putting 
melanocytes under continuous oxidative stress. In response to this danger, the melanocytes 
have developed the membrane-bound melanosomes to localize these substances and 
prevent cellular damage.(20) In contrast to it derivatives, melanin acts as a strong antioxidant 
and has the ability to scavenge free radicals. The melanosome thus functions to take up and 
store cytotoxic metabolites and waste products. It is thought that this property, although 
helpful in maintaining a toxin free intracellular environment in healthy skin cells, might act to 
sequester chemotherapeutic agents in melanoma cells, thus facilitating chemoresistance.(3) 
 
These mechanisms enable melanoma to become therapeutically resistant, causing tumours 
to persist, metastasize, and recur with heightened tumorigenic power.(21) These facts are 
indicative of a need for new therapeutic techniques that can address currently unmet clinical 
requirements. Photodynamic therapy (PDT) has the potential to meet these needs.  
 
1.2 PHOTODYNAMIC THERAPY 
1.2.1 Principles of photodynamic therapy 
PDT involves the irradiation of a photosensitizer (PS) in the presence of molecular oxygen to 
produce cytotoxic levels of ROS and singlet oxygen (1O2) that can overwhelm resistance 
mechanisms and induce cell death through apoptosis, necrosis or autophagy.(20, 22) While the 
PS is harmless in its natural ground state, light activation within its absorption spectrum 
causes its fluorescent and cytotoxic properties to become activated. The absorption of 
photons raises the PS to an excited singlet state, where it is unstable and subsequently decays, 
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returning to its ground state. In this event, fluorescence will be emitted, allowing for 
visualization of the PS. At the wavelength of peak absorption, the PS undergoes ‘intersystem 
crossing’, which results in an excited triplet state. The interaction between this excited PS and 
neighbouring molecules leads to the production of ROS through two mechanisms: 1) The Type 
I photo-oxidative pathway induces the transfer of electrons or hydrogen atoms from the PS 
to nearby biomolecules that then react with oxygen to produce superoxide ions, peroxides 
and hydroxyl radicals, which trigger free radical reactions. 2) In the Type II pathway, the 
energy released when the PS falls back to its ground state is transferred to ground state 
oxygen, creating 1O2 (Figure 2). Oxygen is thus essential in the process, and it can be shown 
that the quantum yield of the ROS produced is proportional to the amount of oxygen available 
in the tissue, which directly affects the efficacy of the therapy.(23)  
Although still emerging and not yet FDA approved, PDT has been approved for clinical trial; it 
has produced successful results for the treatment of several non-malignant skin diseases and 
malignant skin cancers(12, 22, 24). While various mechanisms of cell death have been observed 
in PDT, the exact mechanisms of PDT-induced cell death remain to be fully characterised 
(Davids 2008). 
  
Figure 2: Energy levels diagram of PS excitation. The three components of PDT – PS, molecular oxygen and coherent light – 
result in production of ROS radicals and 1O2.(25) PS: photosensitizer, Es: excited singlet, Et: excited triplet, O2: dioxygen, 1O2: 
singlet oxygen, ROS: reactive oxygen species. 
 
 
1.2.2 Mechanisms of cell death  
Several cell death mechanisms exist; the predominantly observed forms in PDT-induced cell 
death are apoptosis, necrosis and autophagy,(20) with immunogenic cell death (ICD) having 
been only recently identified.(26)  
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1.2.2.1 Autophagy 
Under nutrient stress, cells undergo the self-degradative process of autophagy. In this 
process, autophagosomes engulf proteins and cytoplasm and then bind with lysosomes, 
where their content undergoes degradation.(27) There are three different mechanisms 
through which autophagy is activated: macroautophagy, microautophagy and chaperone-
mediated autophagy.(27, 28) Several pathways control the autophagy process, including the 
PI3K/Atk/mTOR pathway. This pathway is often defective in melanoma cells; the 
phosphorylation of mTOR upstream causes a kinase cascade that ultimately leads to the 
inhibition of autophagy.(27)  
 
1.2.2.2 Apoptosis 
Apoptosis, currently the best understood mechanism of cell death, can be instigated by one 
of three pathways: the intrinsic, extrinsic, or granzyme pathway. The intrinsic (or 
mitochondrial) pathway can be activated through environmental pressures such as oxidative 
stress, nutrient starvation and UV exposure. Members of the pro- and anti-apoptotic Bcl-2 
family regulate this process by increasing the permeability of the mitochondrial membrane, 
which causes cytochrome c to leak into the cytoplasm.(27, 29) Photodamage to the 
mitochondria or ER can also lead to destruction of the anti-apoptotic proteins, Bcl-2 and Bcl-
xL.(30) Moreover, the effects of mitochondrial photodamage may be partially alleviated by 
autophagy,(31) but not if the target of PDT is the lysosomes.(32) The extrinsic pathway is 
dependent upon the binding of FasL to Fas and TNFα to TNFR, which leads to the activation 
of an intracellular death domain, whereas the granzyme pathway is activated by cytotoxic T 
cells. This elicits the release of granzyme, which results in the cleavage of caspases.(27) 
 
However, it has been observed that melanoma cells are able avoid apoptosis through 
various mechanisms,(33) leading to an acquired apoptosis-resistance to many common 
cancer therapies.(27, 34) It is thus suggested that treatments that induce necrosis/necroptosis 
might be beneficial. 
 
1.2.2.3 Necrosis 
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Necrosis commonly results from external cellular injury, e.g. photodamage, loss of 
membrane integrity and cell lysis.(30) Regulated necrosis, also referred to as necroptosis, is 
driven by kinases such as RIPK1 and RIPK3 and is not caspase-dependent.(27) The process 
occurs via the RIPK1/RIPK3/MLKL pathway and is negatively regulated by caspases, which 
cleave RIP1 and RIP3.(35) During this form of necrosis, the permeability of the plasma 
membrane increases, and it becomes damaged, leading to the release of damage-associated 
molecular patterns (DAMPs). However, low RIPK3 expression in melanoma cells can cause 
dysregulation of this process.  
 
PDT has been shown to kill cells predominantly through necrotic cell death, unlike 
chemotherapy- and radiation-induced cell death, which triggers apoptosis by altering cell-
cycle checkpoints.(20) During NIR PDT, cells are observed to swell due to rapid changes in 
membrane permeability that cause dramatic changes in osmotic pressure; thereafter, they 
rupture and release their intracellular contents.(36) Nevertheless, further research on the 
mechanisms on PDT-induced cell death are still necessary, as this process is not fully 
understood.  
 
1.2.2.4 Immunogenic cell death 
ICD occurs when damaged and dying cells release DAMPs. DAMPs are found endogenously 
and typically contribute to normal functions intracellularly; however, when they become 
exposed extracellularly, e.g. through cell rupture after NIR PDT, they gain immunogenic 
properties. After extracellular release or membrane exposure, these molecules alert the 
immune system to danger through interactions with pattern recognition receptors (PRRs). 
PRRs are expressed on various cells in the innate immune system, e.g. dendritic cells, 
monocytes and macrophages. Their interaction with DAMPS promotes the activation and 
maturation of the immune cells, which then present the TAA to the T cells, thus facilitating 
an adaptive anticancer immune response.(37, 38)  
 
There are four know modes of ICD: 1) Necroptosis (not accidental necrosis), 2) Pathogen-
driven ICD, 3) ICD due to certain chemotherapeutics that target essential cell compartments 
that induce cell death pathways, and 4) activation of ICD through physical cues, such as 
through hypericin PDT or irradiation.(37, 39, 40) Apoptosis has previously been thought not to 
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induce any immune effects, and necrosis has been thought to be the only cell death 
mechanism to produce an inflammatory response.(20) However, recent findings contradict 
this opinion; research on ICD has shown that apoptosis does in fact have some 
immunogenic abilities. ER stress, such as that caused through targeted PDT or in some 
chemotherapies, is thought to be essential to the occurrence of ICD.(37) Thus, a combination 
of both regulated necrotic cell death and apoptotic cell death might be favourable in cancer 
therapy. Moreover, given that it can elicit an enhanced immunologic effect, PDT may have 
important implications for the treatment of metastatic cancers.(41)  
 
 
1.2.3 Photodynamic therapy and melanoma  
A plant-derived PS called hypericin has shown some promise in melanoma treatment. 
Hypericin is a compound extracted from St John’s Wort (Hypericum perforatum L.) that 
absorbs UVA (315-400nm, with peak absorbance at 351nm) and visible light (548-593nm, with 
peak absorption at 563nm) and emits at 594-642nm, with peak emission at 600nm, and has 
shown to be effective in eliminating cancerous skin cells in vitro.(3, 42)  Hypericin PDT studies 
reveal that unpigmented melanoma cells die predominantly via apoptotic pathways, while 
pigmented melanoma cells die predominantly via necrotic pathways. The most plausible 
explanation for this is that the melanin provides photoprotection by absorbing UV light and 
preventing the production of ROS and inevitable apoptosis. Damage to the melanosomes 
membrane, however, results in leakage of cytotoxic melanin precursors into the cytoplasm, 
leading to necrosis. This is evidenced by the fact that localization of hypericin in the 
melanosomes is seen in pigmented melanoma.(20, 22, 43)  
Despite successful in vitro outcomes, and although hypericin is a second-generation PS, 
designed to provide increased tumour accumulation and triple quantum yield, hypericin 
nonetheless suffers several limitations. Due to the aggressive VGP of the cancer, it is 
necessary that treatment penetrates deep into the skin, beyond its superficial layers. Visible 
and UV light fail to do so, which means that hypericin PDT in humans would fail in eliminating 
some population of cancerous cells, resulting in subcurative treatment. PDT performed within 
these absorption ranges would also be inefficient in highly pigmented melanomas due to the 
photoprotective properties of melanin.(44) In addition, the absorption  spectrum of hypericin 
overlaps with that of haemoglobin, limiting the photoactivation of the PS. (45, 46) Furthermore, 
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prolonged treatment with UVA can lead to photo-aging and carcinogenesis. In addition to its 
suboptimal absorption spectrum, hypericin is hydrophobic, which means that it must 
permeate passively into the cells in order to produce intracellular ROS and has limited 
efficiency, because it must be internalised into the mitochondria and other organelle to 
produce its effects. Its hydrophobic nature also makes conjugation to antibodies more 
difficult as it compromises the immunoreactivity and in vivo accumulation.(20, 22) 
There are many factors to be considered when selecting an appropriate PS with regards to 
the excitation and emission wavelengths and their properties.  These factors can affect our 
ability to activate the PS and to detect its activity, heavily influencing the success of a PDT 
treatment. The use of near-infrared (NIR) dyes holds particular promise and offers various 
advantages over hypericin. 
 
1.2.4 Near-infrared photosensitizers 
NIR fluorescent dyes have several benefits over conventional fluorophores. The optical 
properties of NIR decrease light absorbance and scattering while increasing the depth of 
tissue penetration of the light up to several millimetres relative to visible light fluorescence 
(Figure 3). This is largely due to the fact that many biomolecules, such as oxyhemoglobin, 
deoxyhemoglobin and water, exhibit minimal absorption in the NIR range. As a result, NIR 
signals are more versatile and produce lower background, thus improving the tumour-to-
background ratio (TBR) when accumulated in tumour tissue. Additionally, the extinction 
coefficient, which relates to how strongly a PS will absorb light, is up to 17-fold higher in NIR 
dyes compared to conventional PSs. Hypericin and the NIR PS IRDye 700DX (IR700), have 
extinction coefficients of 10 000 M-1cm-1 and 165 000 M-1cm-1, respectively. The low 
extinction coefficient of hypericin indicates that many more molecules of hypericin are 
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needed to elicit comparable effects to IR700. Overall, the phototoxicity per photon absorbed 
is more efficient in NIR agents than in conventional agents. (47-52) 
Figure 3: Image depicting the depth of tissue penetration from the UV to IR range. The bright red bar, 650-1000nm, includes 
the NIR range, where tissue penetration is maximal.(53) 
 
 
IR700 is a dye of particular interest for NIR PDT. It absorbs light at 658-758nm, with peak 
absorption at 689nm (Figure 4).(54, 55) IR700 was originally developed for its fluorescent 
properties and its cytotoxic properties were only recently discovered. It has therefore become 
an incredibly useful theranostics agent, i.e. it is a single molecule that can be used as both a 
therapeutic and an imaging tool. It has previously been shown to be successful in eliminating 
the malignant cells of several cancers both in vitro and in vivo in xenograft mouse models.(26, 
55-59) Furthermore, studies using this dye have shown that repeated light exposure with IR700 
is not only safe but also facilitates complete eradication of the tumour. This is because, unlike 
in ionizing radiation therapies that use gamma rays or x-rays, there is no dose limitation for 
NIR light irradiation. NIR could therefore accommodate the long-term management of 
tumours.(48) Repeated exposure of the tumour to NIR irradiation also becomes vital when 
considering that subcurative PDT can lead to increased expression of vascular epithelial 
growth factor (VEGF), which is a lead player in angiogenesis.(60, 61) PDT creates hypoxia by 
consuming the available oxygen and damaging the vasculature, triggering a compensatory 
synthesis of VEGF. If repeated rounds of irradiation could not be performed, this would make 
patients vulnerable to increased angiogenesis and metastatic growth.(62, 63) 
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Figure 4: IR700 absorption and emission spectra (in water). Peak absorption at 689nm, peak emission at 700nm.(50) 
 
Cell death appears to begin almost instantaneously with IR700 and persists for several days 
after light exposure. This immediate effect is indicative of the fact that NIR agents result in 
rapid necrotic cell death, as opposed to relying on the production of ROS and cell death 
through slower apoptotic pathways initiated by conventional PSs. This necrotic death is likely 
caused by physical injury, whereby membrane disruption occurs due to a local increase in 
heat upon light exposure, resulting in pressure waves.(48, 55) Research does show that there is 
some cell death due to ROS and apoptosis, although this effect accounts for only about 25% 
of the total cell death.(64) 
Unlike hypericin and other conventional PSs, IR700 is hydrophilic. It is thus easily bound 
covalently to an antibody. Its lipophobic nature means that it does not freely enter cells and 
thus will not accumulate in tissue at random. It has been shown to have equal cell death 
effects when it is irradiated only once internalisation of the PS has occurred as with irradiation 
upon surface binding. Although, when internalised, monoclonal antibody (mAb)-IR700 
conjugates show co-localisation with the endolysosomal compartment and damage to the 
membrane and lysosomes upon activation, internalisation is not necessary for efficient 
cytotoxic activity. Membrane binding, however, must occur in order to elicit targeted 
effects.(48, 64) 
PDT is an underused therapy that has great potential, but also has much room for 
improvement. PDT depends on the passive accumulation of the PS compound in tumour 
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tissue. The technique thus lacks specificity and, while the effect is significantly less than that 
of traditional chemo- and radiotherapies, healthy tissue surrounding the tumour is damaged. 
This is referred to as the scattergun effect, and can lead to side effects, such as off-target 
necrosis and extensive photosensitivity.(65) Antibody technology enables us to greatly reduce 
systemic and dose limiting toxicity through the use of photoimmunotherapy (PIT). 
 
1.3 ANTIBODY TECHNOLOGY 
1.3.1 Monoclonal antibodies and antibody-drug conjugates 
The discovery that malignant cells express tumour-associated antigens (TAAs) and altered 
receptor profiles has given rise to the potential for immunologically based diagnostic and 
therapeutic strategies in the form of mAbs. Cancer is a heterogeneous disease in which each 
subtype exhibits a distinct pattern of genetic dysregulation, resulting in a unique cell surface 
receptor expression profile.(66) Melanoma itself is a heterogeneous cancer with multiple 
causal pathways or aetiologies.(67) mAbs (such as trastuzumab, developed for the treatment 
of HER2-positive breast cancers(68, 69)) are capable of selective biorecognition and can thus 
target specific tumour cell receptors.(70) In melanoma, targets of interest include 1) the pro-
angiogenic marker VEGF, 2) the negative T cell regulator, cytotoxic T-lymphocyte antigen-4 
(CTLA4), expressed on T lymphocytes, 3) the migration promoting chondroitin sulphate 
proteoglycan 4 (CSPG4), 4) CD25 expressed on suppressive regulatory T cells (Tregs), and 5) 
the immune checkpoint programmed cell death-ligand 1 (PD-L1) expressed on antigen 
presenting cells and tumour cells.(71-74)  
 
Upon antibody-antigen binding, cell death might occur through one of four ways: 1) inhibition 
of a signalling pathways results in desirable downstream effects, such as disruption of 
proliferation and survival pathways, 2) the antibody-dependent cellular cytotoxicity (ADCC) 
and immune response are activated via the fragment crystallizable (Fc) region, 3) the 
complement-dependent cytotoxicity (CDC) and cell lysis via the Fc region, or 4) drugs are 
delivered in the form of an antibody-drug conjugate (ADC) (Figure 5)(66, 75, 76): this is what is 
referred to as immunotherapy, whereby antibodies are used to direct modulatory effects to 
a specific cellular target.(66) This ability to target selective cell surface markers unique to a 
specific disease modality enables us to overcome the problem of passive and off-target drug 
accumulation that is associated with PDT. Drugs can be delivered selectively to cells of our 
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choosing, eliminating systemic side effects. Several ADCs have been developed and approved 
for cancer immunotherapy.(77-80)  
 
Figure 5: Diagram of an antibody-drug conjugate. A payload, i.e. the biologically active cytotoxic molecule comprised of a 
linker and a warhead responsible for cell death, conjugated to a monoclonal antibody.(81) 
 
ADCs have gained popularity over naked mAbs because the latter are limited in their efficacy 
in so far as the inhibition of a particular receptor can facilitate cell death or elicit an immune 
response. It is also of benefit that the conjugation of a PS to a ligand increases its serum half-
life, thus increasing its duration of blood circulation. This allows for unbound conjugate to 
redistribute and bind to more target cells.(55) Furthermore, because cancers can become 
resistant to directed mAbs, attaching a drug molecule to the mAb greatly increases the 
likelihood of successful treatment, as ADCs allow for directed and highly controlled drug 
release. The combination of selectivity and controllable release means that lower dosages of 
ADCs compared to mAbs can elicit comparable responses. Resistance to a particular ADC will 
therefore develop significantly later than that of the constitutive mAb alone, thus widening 
the therapeutic window.(82) Although immunotherapy has seen great progress in recent years, 
traditional ADCs have several limitations that make them suboptimal therapeutic agents. 
 
1.3.2 Limitations of monoclonal antibodies and traditional ADCs 
While ADCs are currently being used widely in cancer therapy(77-80), they have limitations. One 
limitation is the current lack of versatility and personalisation of these drugs, given the 
heterogeneity of the disease. Trastuzumab, for example, treats HER-positive breast cancers, 
which make up only about 25% of breast cancers. The remaining 75% of patients, in whom 
the HER2 antigen is absent, can see no benefits from the drug and, for patients with triple 
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negative breast cancer, no alternative mAb therapy exists.(83) As for melanoma, only three 
mAb treatments have been approved by the FDA. Nivolumab and pembrolizumab target 
programmed cell death protein 1 (PD-1) and ipilumimab targets CTLA4.(84-86) This narrow 
selection of targets means that non-responsive patients lack alternative options. 
Moreover, the specificity and sensitivity of traditional ADCs is not optimal. ADCs are typically 
formed by cross-linking the cysteine or lysine amino acid side chains of an antibody with the 
drug. This leads to heterogeneous conjugates, as linking can happen across any of the twelve 
available residue side chains. Thus, not only does the configuration of each conjugate differ, 
but so does the number of drug molecules attached to each, i.e. the drug-to-antibody ratio 
(DAR) (Figure 6). As a result, the pharmacokinetic properties, efficacy and safety profile of 
each individual ADC differs. Moreover, when the DAR is too high (>4), the body might reject 
the conjugate as a damaged protein and rapidly clear it from the body. Drug load is therefore 
an imperative consideration in the design of ADCs.(11, 81, 87, 88) 
 
Figure 6: Traditional antibody-drug conjugates produce heterogeneous populations. Heterogeneous products have varied 
drug-to-antibody ratios.(81) 
 
Another obstacle regarding ADCs is the preservation of the antibodies’ structural integrity 
and biological functioning during and after the conjugation process.  These properties are 
negatively impacted by factors such as the pH, toxicity and temperature of the environment 
in which the chemical reaction takes place. In addition, the drugs themselves can affect the 
properties of the antibodies. Any resulting changes to the antibody can in turn affect its 
binding properties and thus its targeting specificity(89). Lastly, the first generation of mAbs and 
ADCs are not humanised, but rather derived from murine antibodies. This can lead to 
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immunogenicity whereby the human immune system is unable to bring about CDC and ADCC 
via the Fc, and human anti-mouse antibodies are produced to attack the foreign antibodies(76).  
SNAP-tag is a unique antibody format technology that can overcome the above-mentioned 
limitations. The conjugation, targeting, cytotoxic efficiency and safety of ADCs can be greatly 
increased through the use of SNAP-tag technology.  
 
1.4 SNAP-TAG TECHNOLOGY 
1.4.1 Technical background 
O6-Alkylguanine-DNA alkyltransferase (hAGT) is the human DNA repair enzyme that removes 
DNA alkyl adducts from the O6 position of guanine and transfers the alkyl group to one of its 
reactive cysteine residues (Cys145) to release guanine. Benzylguanine (BG) reacts readily as a 
substrate for hAGT. Exposure to BG results in the covalent bonding of the two molecules, 
causing the protein to become irreversibly inactivated.(90-92) SNAP-tag is an engineered 
version of this enzyme, which exploited this chemistry and can mimic it with any BG-modified 
substrate, creating a self-labelling fusion protein. Unlike traditional ADCs, which rely on 
additional conjugation steps that require chemical and enzymatic catalysts, this reaction is 
autocatalytic, which greatly simplifies the labelling process.(93) The reaction creates a covalent 
bond between SNAP-tag and any BG-modified molecule as the benzyl alkyl group is 
transferred to the SNAP-tag protein’s reactive cysteine residue and guanine is released to 
produce a stable tioether (Figure 7). This coupling between SNAP-tag and BG occurs in a 
precisely 1:1 stoichiometry and at a distinct binding site,(90, 91, 94, 95) allowing for the production 
of a homogeneous product with a defined configuration and known DAR.(96)  
Figure 7: Depiction of SNAP-tags autocatalytic chemical reaction. An irreversible covalent bond is formed between SNAP-
tag and BG derivatives as the benzyl alkyl group is transferred to the protein cysteine residue and guanine is released to 
produce a stable tioether(97) 
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Directed evolution of hAGT has decreased SNAP-tag’s binding affinity for DNA and reduced 
its size, rendering a 182 amino acid mutant that is 50 times more reactive than the wild 
type.(91, 92, 98)  Removal of unessential cysteine residues facilitates folding of the protein under 
oxidative conditions, and additional mutations have made SNAP-tag resistant to hAGT 
inhibitors.(99) Furthermore, because SNAP-tag is of human origin it does not require 
humanization to overcome the problem of immunogenicity and the risk of an induced 
immune response is minimized, making it a feasible agent for in vivo application in humans.(100) 
SNAP-tag can be genetically fused to any ligand of choice, creating a fusion protein. Of interest 
in the current study is the scFv-SNAP construct, in which SNAP-tag is cloned with a single chain 
variable fragment (scFv) of the antibody of the cell surface receptor of interest fused at its N-
terminus. A polypeptide linker is used to connect the variable heavy and light chains to form 
an scFv fragment (Figure 8). The scFv is the antigen-binding moiety of the antibody and is the 
smallest functional format in which the antibody’s receptor-binding properties can be 
preserved.(101) Although removal of the Fc region means removal of the ADCC and CDC 
responses, such recombinant fragments are better suited than mAbs as ADCs because they 
allow for easy site-directed conjugation of the drugs to the antibody(76). Nonetheless, these 
fragments do not typically withstand direct chemical modification, and the integrity and 
functionality of the protein, and sometimes the effector molecule, is therefore compromised 
in such procedures and it has been shown that there are detrimental effects when an 
antibody undergoes direct conjugation to a fluorophore.(89, 102) SNAP-tag addresses this 
problem by providing a proxy for chemical modification with no harmful effects on the 
ligand.(96, 103) Moreover, scFv-SNAP fusion proteins are ideal because of their relatively small 
size of about 50 kDa.  
Figure 8: Examples of various antibody formats. Full-length antibody (left) with crystallizable (constant) region (Fc) and 
antigen-binding region (Fab), containing variable regions (Fv) of the heavy (VH) and light chains (VL) (top right). Single-chain 
variable fragment (scFv) comprised of VH and VL variable regions connected via a polypeptide linker (bottom right).(104) Fc: 
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fragment crystallizable, Fv: vairable fragment, VH: heavy chain, VL: light chain, Fab: antibody-binding fragment, scFv: single 
chain variable fragment. 
 
 
1.4.2 Size, circulation and clearance 
The size of the scFv-SNAP probe affects both its ability to penetrate tissue and the rate at 
which it is cleared from circulation.(105) Because deletions in the SNAP-tag gene sequence have 
reduced its size (20kDa) compared to that of the wild type AGT protein or endogenous 
fluorescent proteins, SNAP-tag has a much higher degree of penetrability than its larger 
counterparts. It is in fact largely unrestricted in its ability to access any cellular 
compartment.(92) In combination with an scFv, this protein has a total size of approximately 
50 kDa. It has been shown that the reduced size of an scFv results in higher uptake of the 
probe into tumour tissue, resulting in a superior TBR, compared to that of the full-length 
mAb.(102) While full-length antibodies tend to exhibit superior tumour retention, their large 
hydrodynamic radius (∼5 nm) hinders their renal filtration.(105) The intermediate size of the 
scFv-SNAP construct facilitates rapid accumulation and efficacious tumour binding soon after 
injection together with rapid renal clearance. scFv-SNAP fusion proteins have been shown to 
accumulate in the kidneys shortly after administration, and subsequently in the bladder.(57, 92, 
105-107) This further enhances the tumour signal as excess probe is rapidly cleared from the 
bloodstream, minimizing background interference during visualisation.  
All of the above-mentioned attributes make SNAP-tag an attractive agent for application in 
cancer detection, subtype classification and diagnosis, and cell-specific drug delivery. It is a 
highly promising tool for precision medicine and, together with IR700, has great potential in 
PIT. 
 
1.4.3 Photoimmunotherapy 
PIT combines the cytotoxic power of photodynamic therapy with the targeting precision of 
immunotherapy to form an antibody-photoabsorber conjugate (APC). Thus, while PDT 
depends on the passive accumulation of drugs in the tumour tissue, PIT is an active targeting 
strategy.(56, 108) The adoption of SNAP-tag technology into PIT offers a simple solution to 
various issues associated with mAbs and ADCs. SNAP-tag protects the antibody from possible 
chemical alterations caused by conjugation, increasing the specificity and efficacy of the agent. 
It produces homogeneous conjugates, allowing for a defined DAR and thus measurable 
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kinetics and safety profiles. It eliminates off-target accumulation and prevents the damaging 
scattergun effect of PDT, reducing systemic toxicity. Proof of concept for SNAP-tag-based PIT 
was shown in 2011, when Hussain et al. used the anti-EGFR antibody fragment, scFv-425 to 
create scFv-425-SNAP fusion proteins conjugated to the chlorin e6 PS to target and kill EGFR-
positive epithelial cancer cells.(109) 
Because of the innate fluorescent properties of photosensitizing agents, the same molecule 
can be used to image a tumour, treat cancer, monitor accumulation of the PS and track 
treatment-induced changes (such as size, location and receptor expression). Tumours can be 
both assessed through real-time monitoring and treated non-invasively simply by changing 
the wavelength of the light to which the agent is exposed.(58, 109, 110) Conventionally, tumours 
have been evaluated by biopsy and morphological examination. However, these methods are 
invasive, and they fail to evaluate the tumour in its entirety. They rely on pathological changes 
that are typically late stage indicators of tumour progression, such as change in size and gross 
morphology.(111, 112) Ultimately, PIT is a theranostics approach, allowing for both diagnosis and 
treatment at an early stage. 
Current diagnostic methods are invasive and are susceptible to both false-negatives and false-
positives. This results in late stage detection, and consequentially poor prognosis, or patients 
with subclinical or benign cancers undergoing unnecessary harmful and expensive 
treatment(113). Additionally, current methods of cancer treatment, such as chemotherapy and 
radiation, cause many unpleasant side effects and are not equally effective on all patients(114). 
This is largely due to the heterogeneity of the disease and reiterates the need for targeted 
therapies using molecular techniques, subtype classification of individual cancers, and 
personalised and precision treatments.  
The selectivity of PIT means not only that tumour cells can be targeted without harm to 
healthy cells but also that the individual can be screened for the particular receptor signature 
of their tumour, and the appropriate probe can then be administered, personalising the 
therapy. In the case of melanoma, programmed death-ligand 1 (PD-L1) is particularly 
interesting for diagnostic and prognostic purposes, while CSPG4 is an ideal target for diagnosis 
as well as the selective delivery of drugs to target cells. 
 
 25 
 
1.5 PROGRAMMED DEATH-LIGAND 1 
1.5.1 Tumour immune response  
The discovery of TAAs has occurred fairly recently but has rapidly given way to an entirely 
new understanding of cancer. TAAs are generally self-antigens that are expressed unusually 
in the tumour, e.g. they might be mutated or over-expressed, but they could also be tumour-
specific antigens (TSAs).(115) Though our knowledge in this area is still lacking, we now know 
that malignant cells express TAAs and that these, along with tumour infiltrating lymphocytes 
(TILs), in particular the TAA-specific CD8+ cytotoxic T lymphocytes (CTLs), influence immune 
surveillance of the tumour microenvironment.(116) CTLs have been found within the tumour 
and its microenvironment, which indicates that cancer triggers the immune responses of its 
host. This response is mediated by the TAAs, which serve to discriminate between malignant 
and healthy cells.(117) The identification of these antigens has been of great value in the 
immunodiagnosis of several cancers, including hepatocellular carcinoma, ovarian cancer, 
breast cancer and osteosarcoma.(118-121) These studies used autoantibody detection panels to 
determine the presence of cancer. CTLs recognize TAAs that are presented by the MHC I 
receptors via the T cell receptors (TCRs).  
1.5.2 PD-L1 expression and functional role 
The PD-L1 ligand and its corresponding receptor, PD-1, are highly expressed on regulatory T 
cells (Treg cells). Tregs are essential for the regulation of peripheral tolerance.(122, 123) The 
PD-1/PD-L1 pathway is responsible for regulating the inhibitory and stimulatory signals that 
govern immunity; in particular, it modulates self-tolerance. When PD-1 is activated through 
binding with PD-L1, its expression is upregulated on T cells. Besides T cells, PD-L1 is also 
expressed on various non-haematopoietic cells, such as in the pancreatic islet cells, muscle, 
nerves and vascular endothelial cells, and in area that have immune privilege, such as the 
eyes and placenta.(124) The interaction between these proteins facilitates T cell tolerance at 
several checkpoint, thus mitigating self-reactive responses from the T cells when dendritic 
cells (DCs) present self-antigens.(125) PD-L1 also aids in inhibiting the function of self-reactive 
effector T cells(126) and in the development and function of the immune-suppressive induced 
Treg cells.(125) 
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PD-L1 has clear advantageous functions in healthy humans. However, in a cancerous person, 
the disadvantages of its expression are apparent. In these circumstances, the aberrant 
expression of PD-L1 becomes dangerous, as facilitates immunosuppression and self-
tolerance of the tumour, leading to immune evasion. 
 
 
1.5.3 PD-1/PD-L1 immune checkpoint  
When PD-L1, which is often over-expressed on cancerous cells, binds PD-1 receptors on the 
TILs, it inhibits their functionality and proliferation, thus hindering immune responses by 
facilitating peripheral tolerance.(127) PD-1 becomes over-expressed on CTLs in caner patients, 
and coupling with PD-L1 causes their effector function and cytokine production to become 
impaired, leading to “T cell exhaustion”. The PD-1/PD-L1 pathway facilitates immune 
tolerance of tumour cells, aiding the tumour’s evasion of the immune system.(128) The anti-
PD-L1 mAb inhibits the PD-1/PD-L1 pathway and re-establishes antigen-specific CTL function, 
thus counteracting the immunosuppressive tumour microenvironment.(70)   
PD-L1 has been shown to be over-expressed in both its full-length form and in several splice 
variant forms in malignant melanoma cells, however; other studies have found little relevant 
PD-L1 expression on melanoma tissue. (129, 130) Nonetheless, two mAbs targeting this pathway, 
pembrolizumab and nivolumab, have been approved for clinical use and are showing 
improved survival in patients.(131, 132) 
 
1.6 CHONDROITIN SULPHATE PROTEOGLYCAN 4 
1.6.1 Characteristics and expression 
CSPG4, also known as high molecular weight melanoma-associated antigen (HMW MAA) or 
melanoma-associated chondroitin-sulphate proteoglycan (MCSP), is the analogue of the rat 
brain progenitor marker, NG2. It is a cell surface antigen, first discovered on human 
melanoma cells and is often overexpressed in melanoma tumours.(133-135) It is a type I 
transmembrane chondroitin sulphate-modified glycoprotein-proteoglycan that is able to 
interact with cytoplasmic components as well as extracellular matrix components, thus 
mediating downstream signalling pathways. It is anchored to the actin filaments of the 
cytoskeleton (Figure 9), influencing actin polymerization, cell adhesion and motility.(136-138) It 
acts through the ERK and FAK pathways to influence tumour cell survival and proliferation, as 
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well as migration and invasion, thus contributing to melanoma’s ability to grow and 
metastasize. CSPG4 plays a significant role in the regulation of various cell cycle pathways and 
in the promotion of EMT.(139-142)  
Figure 9: Schematic representation of the protein domain organization of CSPG4. Three extracellular domains (D1-3), 
transmembrane region (red) and short cytoplasmic domain.(137) PDZ: post-synaptic density protein 95 (PSD-95), drosophila 
disc large tumor suppressor (Dlg1), zona occludens 1 (ZO-1), D: domain, Cys: cysteine, Ser: serine, Gly: glycine, CSPG4: 
Chondroitin sulfate proteoglycan 4. 
 
CSPG4 is expressed in various developing and immature tissues, as well as on a restricted 
number of adult tissues, including the gut and brain. However, it is post-translationally down-
regulated in the terminally differentiated melanocytes of normal adult tissue.(134, 141-145) Over-
expression of the antigen in malignant cells allows the cancer to evade normal regulatory 
signals, affects the cell-cell interactions that govern anchorage-dependant growth, and is a 
major player in the progression of melanoma into RGP and VGP.(146) CSPG4 is also expressed 
on some stem cells, including cancer stem cells (CSC). CSCs are highly regenerative, self-
renewing (without diminishment of their capacity for proliferation), and have migratory and 
transformation capabilities.(147-149) These cells are highly resistant to therapy and serve as a 
good prognostic marker.(135, 150) These factors make CSPG4 a good target for immunotherapy. 
 
1.6.2 CSPG4 as a therapeutic target 
When choosing an appropriate therapeutic marker, one should be sure that the target 
antigen is differentially expressed on the target cell. It is also imperative that the target 
receptor undergoes minimal secretion into circulation, as the antibody could bind any 
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secreted receptors in the bloodstream, thus using up the probe and limiting exposure to the 
target cells.(151)  
As stated above, CSPG4 has high expression on malignant melanoma cells, with relatively 
limited expression in normal, healthy skin tissue.(75) This target thus satisfies the first 
condition of differential expression on target cells. CSPG4 knockout has been shown to retard 
melanoma tumour growth and migration and promote necrosis and apoptosis of the tumour 
tissue. Furthermore, targeting the antigen with the anti-CSPG4 antibody, mAb9.2.27, 
interrupts tumour growth, while expression promotes anchorage-independent cell growth, 
EMT and survival.(142, 152-154) With regards to the second condition, CSPG4 is a transmembrane 
protein. As such, CSPG4 is permanently membrane-bound, limiting its secretion into 
circulation.(134, 155) 
 
1.7 AIMS AND OBJECTIVES  
1.7.1 Aims 
Given the current limitations of both PDT and ADCs, there are two major changes we would 
implement in order to refine PIT. The first concerns the use of conventional PSs. The second 
concerns the use of mAb. Through the site-directed delivery of theranostics using SNAP-tag 
antibody technology, we aim to achieve photoimmunotheranostic targeting of the CSPG4 
antigen via the anti-CSPG4 antibody, mAb9.2.27, and the photodiagnostic targeting of the 
CSPG4 and PD-L1 antigens.  
mAb9.2.27(scFv)-SNAP-IR700 fusion proteins will be used to target and kill CSPG4-positive 
A375, UCT-Mel-1, UCT-Mel-1-DTIC, WM902, IG-R1, IG-R39 and SK-MEL-28 melanoma cells. 
We hypothesize that the conjugate will show selective binding to these cells and be equally 
effective in eliminating pigmented and unpigmented cell lines in all growth phases, as a) 
melanin absorbs UV light and thus shouldn’t provide photoprotection to pigmented cells in 
the NIR range and b) CSPG4 is reportedly expressed in all growth phases, thus providing the 
suitable target throughout. Since IR700 is effective through membrane binding without 
internalisation, the mechanisms of cell death are expected to be the same in each case – rapid 
injury-induce necrotic cell death. Furthermore, the physical injury to the cell upon NIR light 
exposure is expected to be sufficient in eliminating the chemoresistant cell line, rendering its 
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resistance mechanisms useless, as the cells will not have the chance to internalise and 
sequester or efflux any toxins. 
aPDL1(scFv)-SNAP-Alexa FluorTM 594 (Alexa594) fusion proteins will be used target and 
visualize melanoma cells. It is hypothesized that the above cell lines will express PD-L1 and 
that the conjugate will show selective binding to these. aPDL1(scFv)-SNAP-Alexa594 in 
combination with mAb9.2.27(scFv)-SNAP-Alexa FluorTM 488 (Alexa488) could then be used to 
establish a multiplex ex vivo diagnostic platform.  
The diagnostic abilities and therapeutic efficacy of the combination of PDT and ADCs to 
target both CSPG4 and PD-L1 remains largely unknown. This project therefore aimed to: 
 
1. Generate mAb9.2.27(scFv)-SNAP-Alexa488 and mAb9.2.27(scFv)-SNAP-IR700 to 
target CSPG4 receptors on the above-mentioned cell lines in vitro and determine the 
biological activity of the PIT agent.   
 
2. Generate aPDL1(scFv)-SNAP-Alexa488 to target over-expressed PD-L1 receptors on 
melanoma cells for photodiagnosis. 
  
1.7.2 Objectives 
 Aim (1) will be achieved by: 
 
1. Developing recombinant mAb9.2.27(scFv)-SNAP fusion proteins, through cloning and 
expression of the pCB-CSPG4-SNAP plasmid in a eukaryotic expression vector co-
expressing enhanced green fluorescent protein (eGFP). 
 
2. Enrichment of secreted proteins by immobilized metal affinity chromatography 
(IMAC) and validation of functional protein by western blot. 
 
3. Labelling proteins with BG-modified Alexa488 and IR700 and showing successful 
binding of proteins to target cells by flow cytometry and confocal microscopy.   
 
4. Evaluating phototoxicity to CSPG4-positive cells via PIT through administration of 
mAb9.2.27(scFv)-SNAP-IR700 conjugates and subsequent application of NIR light. 
 
Aim (2) will be achieved by: 
 
1. Developing recombinant aPDL1(scFv)-SNAP fusion proteins, through cloning and 
expression of the pCB-PDL1-SNAP plasmid in a eukaryotic expression vector co-
expressing eGFP. 
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2.  Enrichment of secreted proteins by immobilized metal affinity chromatography 
(IMAC) and validation of functional protein by western blot. 
 
3. Labelling proteins with BG-modified Alexa488 and showing successful binding of 
proteins to target cells by flow cytometry and confocal microscopy.  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2. Methods and Materials 
 
2.1 CELL CULTURE 
2.1.1 HEK293T cell culture 
Human embryonic kidney (HEK293T) cells were cultured in RPMI-1640 medium 
supplemented with 10% foetal bovine serum (FBS) and 100U/mL penicillin-streptomycin. 
Medium was changed every three to four days and cells were passaged when 90% confluent. 
Cells were incubated at 37oC in 5% CO2. All products were purchased from Gibco by Life 
Technologies (CA USA). 
 
2.1.2 Transfection and protein expression in HEK293T cells 
Two days before transfection, HEK293T cells were plated at 70% confluency. The XtremeGENE 
HP DNA Transfection Reagent Quick Protocol (Sigma-Aldrich, MO USA) was used, with some 
alterations. The 3:1 ratio of Transfection Reagent (μL) to DNA (μL) was used, with 5 ng DNA 
per transfection. 9 μL X-tremeGENE HP DNA Transfection Reagent and 190 μL DMEM were 
used. An untransfected cell condition was included as a negative control. 48 hours post-
transfection, cells were observed on a ZOE Fluorescent Cell Imager (Bio Rad, CA USA) for 
detection of eGFP and transfection efficiency was determined through visual cell counting. 
All images were taken at 175x magnification. Cells were then treated with Zeocin to enrich 
the population expressing eGFP. These cells were expanded from T25 flasks to T150 flasks 
(SPL Life Sciences, Gyeonggi-do, Korea) for increased protein production. Cell culture 
supernatant (CCSN) was collected at every medium change, centrifuged at 2500 RPM for 3 
min to remove cellular debris and the remaining cell-free supernatant was stored at 4oC. 
 
2.1.3 Mammalian cell line cell culture 
CSPG4-negative MDA-MB-468 cells and CSPG4-positive SK-MEL-28 (lightly pigmented, RGP), 
HS578T (breast cancer), IGR-1 and IGR-39 (pigmentation and growth phase unknown), and 
CSPG4-negative MDA-MB-468 (breast cancer) were donated by Matthias Peipp of Keil 
University, Germany. CSPGP4-positive A375 (unpigmented, RGP), WM902 (pigmentation 
unknown, RGP), UCT-Mel1 (pigmented, MP) and UCT-Mel1-DTIC-R2 (pigmented, MP, 
chemoresistant) cells were donated by Lester Davids of the University of Pretoria. These cells 
were cultured in DMED medium supplemented with 10% FBS and 100U/mL penicillin-
streptomycin. Medium was changed as required and cells were passaged when 90% confluent. 
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Cells were incubated at 37oC in 5% CO2. All products were purchased from Gibco by Life 
Technologies. 
 
2.2 IN SILICO CLONING 
2.2.1 In silico vector design, plasmid constructs and cloning sites 
SnapGene® software (GSL Biotech, Chicago, IL USA; available at www.snapgene.com) was 
used for in silico design of the mammalian vector system for transient expression of the SNAP-
tag fusion protein. The pCB-H22-SNAP plasmid (8025 bp), previously developed in the MB&I 
lab and derivative of the pSecTag2 A plasmid, containing the sequences for H22(scFv) (747 bp) 
and SNAP-tag (534 bp) was used. H22(scFv), found between the SfiI and NotI restriction sites, 
was removed and the scFv sequence of the mAb9.2.27 (750 bp) or the aPD-L1 antibody (720 
bp), was inserted to produce the final pCB-CSPG4-SNAP (8026 bp) or pCB-PDL1-SNAP (7996 
bp) construct. The open reading frame was translated into annotated base pair and amino 
acid sequences. These translations were used to order the pUC57mAb9.2.27 and pUC57aPD-L1 
production vectors containing the respective scFv inserts, including SfiI and NotI restriction 
sites, from Genscript (NJ USA). 
 
2.2.2 Sequence generation 
To procure a new anti-PD-L1 antibody sequence, a literature search was performed to identify 
an ideal construct from publications and patents and obtain its amino acid sequence. Using 
the Gene Infinity Back Translation Tool (Gene Infinity LLC, San Diego, CA USA; available at 
http://www.geneinfinity.org/sms/sms_backtranslation.html), the amino acid sequence was 
used to translate the nucleotide sequence. IgBLAST (NCBI, Bethesda, MD USA; available at 
https://www.ncbi.nlm.nih.gov/igblast/) was used to analyse the nucleotide sequences of the 
heavy chain (VH) and light chain (VL) variable domains and identify the framework regions (FR) 
and complementarity determining regions (CDR) of each. Each FR and CDR was then 
translated into its corresponding amino acid sequence using the ExPASy Translate Tool (SIB, 
Lausanne, Switzerland; available at https://web.expasy.org/translate/) and CLC Genomic 
Workbench (Qiagen, Hilden, Germany; available at 
https://www.qiagenbioinformatics.com/products/clc-genomics-workbench/) was used to 
align each CDR with the original sequence. 
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2.3 MOLECULAR CLONING 
2.3.1 Liquid transformation of competent cells 
Plasmid DNA was incorporated into chemically competent DH5α Escherichia coli (E. coli) cells. 
Competent E. coli cells (NEB, MA United States) were thawed on ice for 10 minutes. Plasmid 
was diluted to obtain a final concentration of 100 ng/μL. 0.5 μL of plasmid was added to 50 
μL of competent cells, mixed by gently flicking the tube and then placed on ice for 30 minutes. 
The cells were heat shocked in a water bath at 42oC for 60 seconds and subsequently placed 
on ice for 5 minutes. In order to increase the transformation efficiency, 950 μL of room 
temperature Super Optimal Broth with Catabolite repression (SOC) (NEB) was added to the 
mixture. The 1 mL mixture was inoculated into 50mL Luria Bertani Broth (LB) (Sigma-Aldrich) 
and placed at 37oC on a shaker overnight.  
 
2.3.2 Midiprep (large-scale) DNA isolation 
The NucleoBond Plasmid Purification Kit (Macherey-Nagel GmbH & Co, Düren, Germany) was 
used to purify DNA on a large scale (50 mL cultures). Minor alterations were made to the 
manufacturer’s instructions. During the precipitation step the mixture was split into 8x 1mL 
aliquots in 1.5 mL microcentrifuge tubes. These were then centrifuged at 13 200 rpm at room 
temperature for 10 minutes. Each aliquot was then washed in 250 μL 70% ethanol, pellets 
were resuspended, and 4 aliquots were pooled into a tube and centrifuged for 10 minutes. 
Finally, pellets were dissolved in 30 μL sdH2O pre-heated to 50oC to facilitate solubilisation of 
the DNA. The DNA concentration was then quantified using a NanoDrop ND-2000 (Thermo 
Fisher Scientific, DE USA). 
 
2.3.3 Restriction enzyme digestion 
All restriction enzyme (RE) digests were performed using the NEB Double Digest protocol and 
materials, with adjustments. To remove scFv fragments from between the SfiI and NotI 
restriction sites in the vectors, the reaction was set up with 2 μg DNA, 5 μL CutSmart Buffer, 
0.5 μL of SfiI and made to a final volume of 49 μL with sdH2O. The reaction was then incubated 
at 37oC for 4 hours, after which 1 μL of NotI-HF was added and the reaction was incubated at 
50oC overnight.  
 
2.3.4 Agarose gel electrophoresis 
Agarose gel electrophoresis was performed to confirm digestion. A 1.2% (w/v) agarose gel 
(see Appendix 6.3.1) was placed in 1X TAE buffer (see Appendix 6.3.2). 4X Laemmli Load Dye 
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(see Appendix 6.3.2) was added to DNA samples in a 1:10 ratio before loading. Undigested 
template DNA was included as a control. The Quick-Load 1kB DNA Ladder and Generuler 
100bp Plus DNA Ladder (New England BioLabs, MA USA) were used to evaluate the fragment 
sizes. DNA fragments were separated for 60 minutes at 100V using the Mini-Sub Cell system 
(Bio Rad) and then visualized and documented using the UVIpro Gold Gel Documentation 
System (UVItec, Cambridge, UK) under UV light.  
 
2.3.5 Gel extraction 
Agarose bands containing the DNA fragments of interest were excised using the QIAquick Gel 
Extraction Kit (QIAgen, Hilden, Germany), with some changes. Briefly, the gel was visualized 
using the Dark Reader Transilluminator (Clare Chemical Research, CO USA) and bands were 
cut out using a sharp, sterile scalpel. The excised bands were pooled and placed in 1.5 mL 
microcentrifuge tubes. The agarose gel was solubilized by adding enough Buffer QG to fully 
submerge the excised slices, this was considered as ‘three volumes’. Tubes were incubated at 
50oC for 10 minutes, ensuring that the gel was completely dissolved. Tubes were vortexed 
periodically to aid dissolution. One volume isopropanol was added. The solution was placed 
in a spin column inside a collection tube and centrifuged for 1 minute at 13 000 rpm. 
Flowthrough was discarded and the column was centrifuged once more. To wash the column, 
0.75 mL Buffer PE was added and centrifuged for 1 minute.  Columns were placed in clean 
microcentrifuge tubes and, to facilitate solubilisation of the DNA, 50 μL 50oC dsH2O was added 
to the centre of the filter instead of Buffer EB. Tubes were incubated at 50oC for 5 minutes 
before centrifuging for 1 minute to elute DNA. 
 
2.3.6 Ligation 
Ligation of digested fragments was carried out using the NEB T4 Ligase kit and overnight 
protocol (NEB). 20 μL reactions were set up with 2 μL T4 DNA Ligase Buffer, 1 μL T4 DNA 
Ligase, 50 ng vector, and the required amount of insert (dependent upon fragment sizes), 
topped up to 20 μL with dsH2O. Four ligations were performed using 1:1, 1:2, 1:3 and 1:0 
(vector only control) vector-to-insert ratios. The online NEBioCalculator (available at 
https://nebiocalculator.neb.com/#!/ligation) was used to calculate the exact volumes of 
insert required at different vector-to-insert ratios. Transformation efficiency was calculated 
using the following formula:  𝑇𝐸 = (&'(')*+,-. )/[𝐷𝑁𝐴]	(μg/mL) 
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2.3.7 Transformation with recombinant plasmids 
Recombinant plasmid DNA was incorporated into chemically competent E. coli cells. The cells 
were thawed on ice for 10 minutes. Plasmid was diluted to obtain a final concentration of 100 
ng/μL. 0.5 μL of plasmid was added to 50 μL of competent cells, mixed by gently flicking the 
tube and then placed on ice for 30 minutes. The cells were heat shocked in a water bath at 
42oC for 60 seconds and subsequently placed on ice for 5 minutes. In order to increase the 
transformation efficiency, 950 μL of room temperature SOC was added to the mixture, which 
was then placed in an incubator at 37oC for 60 minutes. Cells were mixed thoroughly by gently 
flicking and inverting the tube. 50 μL of mixture was spread on a LB agar plate supplemented 
with 200 ng/μL AMP (see Appendix 6.3.3) and left at 37oC overnight. Vector only and bacteria 
only controls were included. Six single colonies were picked, and each placed in 2 mL LB in 
separate 10 mL conical tubes. The cultures were left on a shaker (220 rpm) at 37oC overnight. 
 
2.3.8 Miniprep (Small-Scale) DNA isolation 
Recombinant plasmids were purified from the E. coli on a small-scale (10 mL cultures) using 
the Zyppy Plasmid Miniprep Kit (Zymo Research, CA USA), according to the manufacturer’s 
instructions, with minor alterations. Briefly, in order to increase the number of bacterial cells 
and thus the final DNA concentration, 1.2 mL culture was placed in a 1.5 mL microcentrifuge 
tube and centrifuged at 16 000 rpm for 1 minute. Thereafter, 600 μL of the supernatant was 
discarded, the pellet was resuspended, and the protocol was continued with the remaining 
600 μL of starter culture. Furthermore, to prevent interference in downstream applications, 
elution was achieved with 30 μL of sterile deionized water (sdH2O), pre-warmed to 50oC, 
instead of Zyppy Elution Buffer. Lastly, rather than standing at room temperature for 1 minute, 
the columns were incubated at 50oC for 5 minutes to facilitate solubilisation of the DNA. The 
eluted DNA concentration was then quantified using a NanoDrop ND-2000. Note, the 
remaining 800 μL of each 2 mL culture was stored at 4oC for potential downstream application 
after confirmation of ligation and sequencing. 
 
2.3.9 Restriction mapping 
Single enzyme digest simulations were performed on SnapGene to predicate the cutting 
patterns of HindIII-HF and BamHI-HF for pCB-H22-SNAP against pCB-CSPG4-SNAP and pCB-
PDL1-SNAP, respectively. The expected band fragments were as follows. HindIII-HF digest of 
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pCB-H22-SNAP: three bands at 6964 bp, 360 bp and 348 bp. HindIII-HF digest of pCB-CSPG4-
SNAP: four bands at 5868 bp, 1450 bp, 360 bp and 348 bp. BamHI-HF digest of pCB-H22-SNAP: 
two bands at 6183 bp and 1840 bp. BamHI-HF digest of pCB-PDL1-SNAP: one band at 7996 
bp. 10 μL reactions were then set up with 2 μg DNA, 1 μL CutSmart Buffer and 0.5 μL enzyme, 
topped up to 10 μL with dsH2O. Samples were incubated at 37oC for 4 hours. Agarose gel 
electrophoresis was performed as described above. Gels were analysed to confirm correct 
ligation of recombinant plasmids, as predicted by the simulation.  
 
2.3.10 DNA sequencing 
Recombinant clones that were confirmed by restriction mapping were bulk prepped and 
purified using the NucleoBond Plasmid Purification midiprep protocol, as described above. 
Samples were sent to Inqaba Biotechnology, as a pay-for-service, in order to confirm the 
accuracy of the open reading frame (ORF) sequence. The universal T7 primer was used, in 
addition to an internal primer with the sequence GCTGATCTATGACGCTAG. Sequencing was 
done with the ABI V3.1 Big dye kit according to manufacturer’s instructions. The labelled 
products were cleaned with the Zymo Seq Clean-Up kit and cleaned products were injected 
on the ABI3500XL. 
 
2.4 PROTEIN PURIFICATION 
2.4.1 Immobilized metal affinity chromatography 
CCSN containing the secreted his6-tagged fusion proteins was first centrifuged in order to rid 
the medium of residual cellular material, as per section 2.1.2. The remaining cell-free 
supernatant (CFSN) was then filtered using the Nalgene vacuum filtration system (Sigma 
Aldrich) with a 0.45 µm Durapore membrane filter (Millipore, MA USA) to exclude remaining 
debris before enrichment by Immobilized Metal ion Affinity Chromatography (IMAC). IMAC 
was performed on an ÄKTA FLPC system (GE Healthcare Europe GmbH, Freiburg, Germany). 
Briefly, a Ni2+-NTA Superflow cartridge column was equilibrated with equilibration buffer (see 
Appendix 6.4.4). CFSN was loaded directly onto the column at a flow rate of 2 mL/min and 
his6-tagged proteins were captured by Ni2+-NTA. The column was washed with equilibration 
buffer. Bound his6-tagged protein was eluted with elution buffer containing 250 µM imidazole 
(see Appendix 6.4.4). Elution buffer was applied at an increasing gradient of 0-30% to 
separate elution peaks. Thereafter a 100% gradient was applied to removal all remaining 
bound protein. 5 mL fractions were collected throughout. 
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2.4.2 Protein concentration 
Amicon Ultra-15 Centrifugal Filter Units (Merck Milipore, MA USA) were used to further 
concentrate purified protein, as well as to remove imidazole. Fractions associated with each 
peak on the ÄKTA chromatogram were pooled in separate Amicon filter tubes, to a maximum 
volume of 15 ml per tube. Tubes were centrifuged at 4000 xg for 25 min, at 4oC. Flowthrough 
was discarded and imidazole-free concentrate was recovered and placed at 4oC. 
 
2.5 PROTEIN ANALYSIS 
2.5.1 Quantification of purified protein  
The concentration of purified mAb9.2.27(scFv)-SNAP and aPDL1(scFv)-SNAP protein was 
determined using a NanoDrop ND-2000 (Thermo Fisher Scientific).  
 
2.5.2 Sodium dodecylsulphate polyacrylamide gel electrophoresis (SDS-PAGE)  
Protein samples were separated by size by SDS-PAGE in order to detect protein in each 
fraction and determine its weigh. 1 μg protein was diluted to a final volume of 20 μL. 5 μL NEB 
4X protein-loading buffer was added to each sample and samples were heated to 95oC for 5 
min before loading. Proteins were separated electrophoretically at 100V for 75 min on the 
Mini-Sub Cell system (Bio Rad). Protein bands were visualised by soaking the gel in Coomassie 
Staining Solution for 30 min. GelAnalyzer software (available at: http://www.gelanalyzer.com) 
was used to determine the size (kDa) of all bands. Briefly, images were uploaded onto the 
program and all intensity peaks were gated, including those of the ladder. The band sizes of 
the ladder were inserted in order to calibrate band molecular weight. Additionally, the 
volume of each band was provided, allowing for the yield of SNAP-tag protein to be estimated. 
Purification fractions corresponding to bands of the appropriate size for mAb9.2.27(scFv)-
SNAP or aPDL1(scFv)-SNAP were pooled for downstream application. 
 
2.5.3 Western blot  
Western blotting was used for the detection of functional his6-tag protein. A gel was run as 
describe in section 2.4.2, with 2 μg of protein. Protein bands were transferred from the gel to 
a nitrocellulose membrane using the electro-tank blotting method at 100V for 75 min. 
Blocking was achieved using 2% milk and PBS for 1 hour at room temperature. A 1:1000 
dilution of anti-His6-tag rabbit primary antibody and a 1:5000 dilution of goat anti-rabbit IgG 
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horse radish peroxidase (HRP)-conjugated secondary antibody (Bio Rad) were used to detect 
proteins. A Gel DocTM XR Gel Documentation System (Bio Rad) was used to visualize protein. 
 
2.6 PROTEIN LABELLING 
2.6.1 Protein labelling with SNAP-Surface® Alexa Fluor® 488 and SNAP-
Surface® 549 
The NEB Protein Labelling in vitro protocol was used to label purified mAb9.2.27(scFv)-SNAP 
and aPDL1(scFv)-SNAP with BG-modified substrates, SNAP-Surface® Alexa Fluor®488 and 
SNAP-Surface® 549, respectively, according to the manufacturers’ instructions. Briefly, a 50 
μL reaction was set up with 42 μL Phosphate Buffered Saline (PBS), 1 μL DTT (50 mM), 5 μL 
SNAP-tag purified protein (50 μM) and 2 μL SNAP-tag substrate (250 μM) and incubated in 
the dark for 30 min at 37oC. Unbound substrate was then removed according to the Zeba Spin 
Desalting Columns 7K MWCO protocol. The final constructs were named mAb9.2.27(scFv)-
SNAP-Alexa488 and aPDL1(scFv)-SNAP-549. 
 
2.6.2 Protein labelling with BG-IR700 
Lyophilized BG-IR700 was solubilised in 50% DMSO. Purified mAb9.2.27(scFv)-SNAP was 
incubated with a two-fold molecular excess of BG-IR700 at room temperature in the dark for 
2 hours. After labelling, unbound dye was removed according to the Zeba Spin Desalting 
Columns 7K MWCO protocol. The final construct was named mAb9.2.27(scFv)-SNAP-IR700. 
 
2.7 IMMUNOASSAYS 
2.7.1. Validation of binding by flow cytometry 
The binding of mAb9.2.27(scFv)-SNAP-Alexa488 to CSPG4-positive cells and aPDL1(scFv)-
SNAP-549 to PD-L1-positive cells was monitored by flow cytometry using a FACSCalibur 
system and FlowJo software for analysis (Becton & Dickinson, Heidelberg, Germany). The 
CSPG4-negative MDA-MB-468 cell line was used as a negative control for mAb9.2.27(scFv)-
SNAP-Alexa488. HS578T was used as a positive control for both probes. In each experiment, 
approximately 1x106 cells were incubated with 5 μL labelled proteins on ice in the dark for 
30min. Cell were fixed for 20 minutes in 4% paraformaldehyde (PFA) and were washed three 
times with PBS before detection. 
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2.7.2 Validation of surface binding by confocal microscopy 
Targeted protein binding was visualized by confocal microscopy. 2.5x104 to 1x105 cells were 
seeded on a cover slip in a 35mm dish and incubated in medium at 37oC in 5% CO2 overnight. 
Cells were incubated with 15 µg mAb9.2.27(scFv)-SNAP-Alexa488 or aPDL1(scFv)-SNAP-549 
in 100 µL serum free medium and 200µL 1:5000 Hoechst counter stain. Excess dye was 
removed by washing cells three times with medium before fixing for 20 minutes with 4% PFA. 
Cells were washed three times with PBS and the cover slip was mounted on a slide. After 
sitting at room temperature for 24 hours, images were captured on the Ziess LSM880 Airyscan 
(Oberkochen, Germany) on the 40X air objective. 
 
 
2.8 EVALUATION OF PHOTOTOXICITY  
2.8.1 Cell viability assay 
Cells were treated with increasing concentrations of unconjugated mAb9.2.27(scFv)-SNAP 
(negative control), mAb9.2.27(scFv)-SNAP-IR700 or Zeocin (positive control). 3 hour later, 
cells were irradiated with 690 nm light at 1.5 W for 90 seconds. Following treatment, the XTT 
Cell Proliferation Kit (Roche, Basel, Switzerland) was used, according to the manufacturers’ 
instructions, to determine cell viability. Briefly, 20 hours after irradiation, cells were incubated 
with XXT solution for 4 hours. The cleavage of the yellow tetrazolium salt by metabolically 
active cells to form orange formazan crystals, which absorb light at 450 nm, was measured by 
spectrophotometry using softMax pro4.3.1 software. The measured absorbance was 
normalized to the untreated control (vehicle). All graphs were created using GraphPad Prism 
software (available at: https://www.graphpad.com/scientific-software/prism/)  
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3. Results 
 
3.1 mAb9.2.27(scFv)-SNAP-IR700 FOR CSPG4-TARGETED THERAPY 
3.1.1 Molecular cloning 
3.1.1.1 In silico vector design 
The pCB-H22-SNAP plasmid contains SNAP-tag between the NotI and BlpI restriction sites and 
H22(scFv) between SfiI and NotI. This plasmid was used as the backbone for the current study. 
H22(scFv) was removed and replaced with mAb9.2.27(scFv) to create the pCB-CSPG4-SNAP 
plasmid. Figure 10A represents the structure of the ORF. Figure 10B is the plasmid map, 
generated on SnapGene. Annotated nucleotide and amino acid sequences were generated 
and used for ordering of the production vector containing the mAb9.2.27(scFv) sequence, as 
well as for alignment (Figure 10C). The alignment confirms that cloning between the SfiI and 
NotI restriction sights will produce an in-frame sequence with no stop codon interference. 
Table 1.1 summarises the components of the pCB-CSPG4-SNAP vector, while Table 1.2 
summarises the plasmids used in this project. 
A 
B 
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Unique Cutters Bold
Sequence:  pCB-CSPG4-SNAP.dna  (Circular / 8026 bp)
Enzymes:  < Unsaved Enzyme Set >  (7 of 653 total)
Features:  25 visible, 25 total
Printed from SnapGene®: 03 Apr 2017 12:21 PM Page 1
NheI
5 ʹ
3 ʹ
95
1 5 10 15 20
M E T D T L L L W V L L L W V P G S T G D A A
1 5
H H H H H
Igκ leader
6xHis
G CT AG CC AC CA TG GA GA CA GA CA CA CT CC TG CT AT GG GT AC TG CT GC TC TG GG TT CC AG GT TC CA CT GG TG AC GC CG CC CA TC AT CA TC AT CA TC
C GA TC GG TG GT AC CT CT GT CT GT GT GA GG AC GA TA CC CA TG AC GA CG AG AC CC AA GG TC CA AG GT GA CC AC TG CG GC GG GT AG TA GT AG TA GT AG
SfiI
190
H A A
1 5
D D D D K A A Q
1 5 10 15 20
P A M A Q V K L Q Q S G P E L V K P G A S
6xHis
enterokinase site CSPG4(scFv)
A TG CC GC CG AC GA CG AC GA CA AG GC GG CC CA GC CG GC CA TG GC CC AG GT GA AA CT GC AG CA GT CT GG AC CT GA GC TG GT GA AG CC TG GG GC CT CA
T AC GG CG GC TG CT GC TG CT GT TC CG CC GG GT CG GC CG GT AC CG GG TC CA CT TT GA CG TC GT CA GA CC TG GA CT CG AC CA CT TC GG AC CC CG GA GT
285
25 30 35 40 45 50
V K I S C K A S G Y A F S R S W M N W V K Q R P G Q G L E W I G
CSPG4(scFv)
G TG AA GA TT TC CT GC AA AG CT TC TG GC TA CG CA TT CA GT AG GT CT TG GA TG AA CT GG GT GA AG CA GA GG CC TG GA CA GG GT CT TG AG TG GA TT GG
C AC TT CT AA AG GA CG TT TC GA AG AC CG AT GC GT AA GT CA TC CA GA AC CT AC TT GA CC CA CT TC GT CT CC GG AC CT GT CC CA GA AC TC AC CT AA CC
380
55 60 65 70 75 80
R I Y P G D G D T N Y N G K F K G K A T L T A D K S S S T A Y
CSPG4(scFv)
A CG GA TT TA TC CT GG AG AT GG AG AT AC TA AC TA CA AT GG GA AG TT CA AG GG CA AG GC CA CA CT GA CT GC AG AC AA AT CC TC CA GC AC AG CC TA CA
T GC CT AA AT AG GA CC TC TA CC TC TA TG AT TG AT GT TA CC CT TC AA GT TC CC GT TC CG GT GT GA CT GA CG TC TG TT TA GG AG GT CG TG TC GG AT GT
475
85 90 95 100 105 110 115
M Q V S S L T S V D S A V Y F C A R G N T V V V P Y T M D Y W G
CSPG4(scFv)
T GC AG GT CA GC AG CC TG AC CT CT GT GG AC TC TG CG GT CT AT TT CT GT GC AA GA GG GA AT AC GG TA GT AG TT CC CT AT AC TA TG GA CT AC TG GG GT
A CG TC CA GT CG TC GG AC TG GA GA CA CC TG AG AC GC CA GA TA AA GA CA CG TT CT CC CT TA TG CC AT CA TC AA GG GA TA TG AT AC CT GA TG AC CC CA
570
120 125 130 135 140 145
Q G T T V T V S S G G G G S G G G G S G G G G S D I E L T Q S P
CSPG4(scFv)
C AA GG AA CC AC CG TG AC CG TG AG TT CG GG TG GC GG TG GA TC CG GT GG TG GC GG CA GC GG TG GT GG CG GC AG CG AT AT TG AA CT GA CG CA AT CT CC
G TT CC TT GG TG GC AC TG GC AC TC AA GC CC AC CG CC AC CT AG GC CA CC AC CG CC GT CG CC AC CA CC GC CG TC GC TA TA AC TT GA CT GC GT TA GA GG
665
150 155 160 165 170 175
A S L A V S L G Q R A T I S C R A S E S V D S Y G N S F M H W
CSPG4(scFv)
A GC TT CT TT GG CT GT GT CT CT AG GG CA GA GG GC CA CC AT AT CC TG CA GA GC CA GT GA AA GT GT TG AT AG TT AT GG CA AT AG TT TT AT GC AC TG GT
T CG AA GA AA CC GA CA CA GA GA TC CC GT CT CC CG GT GG TA TA GG AC GT CT CG GT CA CT TT CA CA AC TA TC AA TA CC GT TA TC AA AA TA CG TG AC CA
760
180 185 190 195 200 205 210
Y Q Q K P G Q P P K L L I Y L A S N L E S G V P A R F S G S G S
CSPG4(scFv)
A CC AG CA GA AA CC AG GA CA GC CA CC CA AA CT CC TC AT CT AT CT TG CA TC CA AC CT AG AA TC TG GG GT CC CT GC CA GG TT CA GT GG CA GT GG AT CT
T GG TC GT CT TT GG TC CT GT CG GT GG GT TT GA GG AG TA GA TA GA AC GT AG GT TG GA TC TT AG AC CC CA GG GA CG GT CC AA GT CA CC GT CA CC TA GA
855
215 220 225 230 235 240
R T D F T L T I D P V E A D D A A T Y Y C Q Q N N E D P L T F G
CSPG4(scFv)
A GG AC AG AC TT CA CC CT CA CC AT TG AT CC TG TG GA GG CT GA TG AT GC TG CA AC CT AT TA CT GT CA AC AA AA TA AT GA AG AC CC TC TG AC GT TT GG
T CC TG TC TG AA GT GG GA GT GG TA AC TA GG AC AC CT CC GA CT AC TA CG AC GT TG GA TA AT GA CA GT TG TT TT AT TA CT TC TG GG AG AC TG CA AA CC
XbaIXhoINotI
950
245 250
G G T K L E L K R A A A L E S R
1 5 10 15
M D K D C E M K R T T L D S P
CSPG4(scFv) SNAP-tag®
C GG CG GG AC CA AG CT GG AA CT GA AA CG GG CG GC CG CA CT CG AG TC TA GA AT GG AC AA AG AC TG CG AA AT GA AG CG CA CC AC CC TG GA TA GC CC TC
G CC GC CC TG GT TC GA CC TT GA CT TT GC CC GC CG GC GT GA GC TC AG AT CT TA CC TG TT TC TG AC GC TT TA CT TC GC GT GG TG GG AC CT AT CG GG AG
C Unique Cutters BoldSequence:  pCB-CSPG4-SNAP.dna  (Circular / 8026 bp)Enzymes:  < Unsaved Enzyme Set >  (7 of 653 total)
Features:  25 visible, 25 total
Printed from SnapGene®: 03 Apr 2017 12:21 PM Page 1
NheI
5 ʹ
3 ʹ
95
1 5 10 15 20
M E T D T L L L W V L L L W V P G S T G D A A
1 5
H H H H H
Igκ leader
6xHis
G CT AG CC AC CA TG GA GA CA GA CA CA CT CC TG CT AT GG GT AC TG CT GC TC TG GG TT CC AG GT TC CA CT GG TG AC GC CG CC CA TC AT CA TC AT CA TC
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Figure 10: In silico design of pCB-CSPG4-SNAP expression vector, containing mAb9.2.27(scFv) and SNAP-tag. A) 
Diagrammatic representation of the structure of the ORF. B) pCB-CSPG4-SNAP plasmid map. D) Annotated protein 
sequence of ORF. EKS: enterokinase site, CSPG4: chondroitin sulfate proteoglycan 4, scFv: single chain variable fragment, 
CMV:, AmpR: ampicilin resistance, IRES: internal ribosome entry site, SV40: simian virus 40, EGFP: enhanced green 
fluorescent protein, bGH: bovine growth hormone, CAP: catabolite activator protein. 
 
 
 
Table 1.1: Summary of plasmids 
 
Plasmid Description Reference 
pCB-H22-
SNAP 
Fusion protein expression vector derived from 
the pSecTag2 A plasmid, containing H22. Also 
used as a dummy construct for restriction 
mapping. 
Previous work by MBI 
https://www.thermofisher.co
m/order/catalog/product/V9
0020 
pUC57mAb9.2.2
7(scFv) 
Production vector containing 
mAb9.2.27(scFv) insert. 
http://www.genscript.com/ve
ctor/SD1176-
pUC57_plasmid_DNA.html 
pUC57αPD-L1 
(scFv) 
Production vector containing αPD-L1(scFv) 
insert. 
http://www.genscript.com/ve
ctor/SD1176-
pUC57_plasmid_DNA.html 
pCB-CSPG4-
SNAP 
Expression vector containing mAb9.2.27(scFv) 
(SfiI/NotI) and SNAP-tag (NotI/BlpI). 
Current study 
  
pCB-PDL1-
SNAP 
Expression vector containing αPD-L1(scFv) 
(SfiI/NotI) and SNAP-tag (NotI/BlpI). 
Current study 
  
pCB-CSPG4-SNAP.dna  (Circular / 8026 bp)
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A CA CT CC CG GG CC TT TG GA CC GG GA CA GA AG AA CT GC TC GT AA GG AT CC CC AG AA AG GG GA GA GC GG TT TC CT TA CG TT CC AG AC AA CT TA CA GC
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A CT TC CT TC GT CA AG GA GA CC TT CG AA GA AC TT CT GT TT GT TG CA GA CA TC GC TG GG AA AC GT CC GT CG CC TT GG GG GG TG GA CC GC TG TC CA CG
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Table 1.2: pCB-CSPG4-SNAP plasmid components 
Component Description 
Igκ leader Secretory sequence, facilitates secretion of fusion protein into the cell 
culture supernatant(66) 
His6-tag High affinity binding to Ni2+-chelating resin for purification . In addition, 
allows detection of fusion proteins with anti-His6-tag antibody(70) 
Enterokinase 
site 
DDDDK cleavage site 
scFv N-terminal single-chain variable fragment  
SNAP-tag® C-terminal self-labelling SNAP-tag protein  
Chimeric 
intron 
Rapid and efficient mRNA export out of the nucleus, significantly increase 
transgene expression 
IRES Allows the initiation of translation from any position within an mRNA 
immediately downstream from where the IRES is located (here, eGFP).(156) 
eGFP Allows for detection of translated protein in HEK293T cells 
bGH Poly(A) 
signal 
Ensures efficient transcription termination and polyadenylation of mRNA(77) 
F1 origin Facilitates rescue of single-stranded DNA 
SV40 
promoter 
Facilitates high-level expression of the Hygromycin resistance gene and 
episomal replication in cells expressing the SV40 large T antigen.(156) 
SV40 ORI Origin of replication 
EM7 
promoter 
Drives expression of the blasticidin resistance gene to allow for selection in 
mammalian cells 
bleO Bleomycin (zeocin) resistance protein for selection in HEK293T cells 
SV40 Poly(A) 
signal 
Efficient transcription termination and polyadenylation of mRNA.(156) 
M13 rev Single-stranded oligonucleotide possessing 5ʹ-hydroxyl and 3ʹ-hydroxyl 
ends and a selection of four fluorescent lables for use in polymerase chain 
reaction (PCR) protocols. Synonym: 5ʹ-CAG GAA ACA GCT ATG ACC-3ʹ.(157) 
lac operator Short region of DNA that lies partially within the promoter and that 
interacts with a regulatory protein that controls the transcription of the 
operon.(158) 
lac promoter Controls transcription of lac operon genes 
CAP binding 
site 
Binding site for catabolite activator protein (CAP), which interacts with 
cAMP and RNAP to activate transcription.(159) 
ORI Origin of replication 
AmpR Ampicillin resistance gene for selection in E. coli  
AmpR 
promoter 
Efficient expression of the Ampicillin resistance gene 
CMV 
enhancer 
Aids efficient and high-level expression of recombinant protein(78, 79, 88) 
CMV 
promoter 
Aids efficient and high-level expression of recombinant protein(78, 79, 88) 
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3.1.1.2 Midiprep DNA isolation 
pCB-H22-SNAP and PUC57mAb9.2.27(scFv) plasmids were bulk prepped to amplify the DNA. After 
successful transformation into and growth of competent E. coli cells, plasmid DNA was 
extracted and purified. Table 2.1 and Table 2.2 show the protein concentration, the 260/280 
ratio and the 260/230 ratio. 260/280 represents the nucleic acid to protein absorbance ratio 
and should sit at ~1.8 when DNA is pure and uncontaminated with protein or reagents that 
absorb at 280nm, such as phenol. 260/230 indicates the presence of contaminants that 
absorb at 230nm, such as EDTA, and should sit at ~2.0-2.2 when nucleic acids are not 
contaminated.(160) The purified plasmid samples were all within the acceptable ranges and 
were thus confirmed for downstream application. 
 
Table 2.1: Quantification of pCB-H22-SNAP plasmid, following large-scale purification 
 
 
 
 
 
 
 
 
Table 2.2: Quantification of pUC57mAb9.2.27(scFv) plasmid, following large-scale purification 
 
 
 
3.1.1.3 Restriction enzyme digestion and agarose gel electrophoresis 
Digestion of both the production vector and the expression vector was successful (Figure 11). 
In the pCB-H22-SNAP expression vector digestion, the large backbone (or vector) fragment 
can be seen at approximately 7000 bp (with the expected size being 7365 bp) and the small 
fragment, relating to the removed H22 sequence, can be seen at approximately 700 bp. 
Although the undigested control appears to weigh less than the digested backbone, this is not 
a true representation of their relative sizes but rather the result of too much DNA being 
loaded in the this well, as can be seen by the high intensity of the band. The pUC57mAb9.2.27(scFv) 
production vector was also successfully digested, with a small band, representing the 
T7 promoter Allows for in vitro transcription in the sense orientation and sequencing 
through the insert.(156) 
Sample Yield (ng/μL) 260/280 260/230 
1 449.9 1.90 2.21 
2 778.1 1.90 2.21 
3 590.3 1.89 2.19 
4 857.7 1.89 2.22 
Sample Yield (ng/μL) 260/280 260/230 
1 4330.1 1.78 2.08 
2 138.3 1.82 2.00 
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mAb9.2.27 scFv insert fragment, seen at approximately 700 bp. Both the backbone and the 
insert were digested with SfiI and NotI and can thus be ligated in frame. 
Figure 11: pCB-H22-SNAP and pUC57mAb9.2.27 RE digests. Fragment sizes were evaluated using a 1kB DNA ladder (MW1) and 
a 100bp+ ladder (MW2). A) pCB-H22-SNAP. An undigested control was used for comparison (lane 1) and six samples were 
digested with SfiI and NotI (lanes 2-7). B) pUC57mAb9.2.27(scFv). An undigested control was used for comparison (lane 1) and 
four samples were digested with SfiI and NotI (lanes 2-5). 
 
 
3.1.1.4 Gel extraction and ligation 
Vector and insert bands were extracted from the gel and purified. The samples with the 
highest concentrations were subsequently used for ligation, i.e. sample 2 of the vector (51.5 
ng/μL; Table 3.1), and sample 1 of the insert (16.5 ng/μL; Table 3.2). During ligation, three 
vector:insert ratios (1:1, 1:2 and 1:3) were used (Figure 12), due to the fact that a new kit was 
used and a standard protocol had not yet been established. Although a 1:3 ratio is 
recommended for this kit, the 1:1 plate showed the best transformation efficiency (1.8x104). 
The vector-only control shows minimal colony formation of autoligated clones, indicating that 
there was some partial digestion in the previous step. The bacteria only control shows no 
colony formation, confirming that all colonies present contain the pCB-SNAP vector. Table 3.3 
contains information regarding the colony formation of each plate.  
 
 
Table 3.1: Quantification of vector purified from agarose gel 
 
 
 
 
Sample  Yield (ng/μL) 
1 45.1 
2 51.5 
3 6.0 
4 7.8 
5 12.7 
6 18.0 
7 15.7 
A MW1  MW2    1          2           3          4           5          6           7 
3 kb 
1 kb 
500 bp 
3 kb 
1 kb 
500 bp 
B  MW1   MW2     1         2         3         4          5      
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Table 3.2: Quantification of insert purified from agarose gel 
 
 
 
 
 
 Table 3.3: Colony formation data 
 
 
 
Figure 12: Ligation of mAb9.2.27 insert and pCB-SNAP backbone to create final recombinant plasmid, pCB-CSPG4-SNAP. 
A) 1:1 vector:insert ligation ratio. B) 1:2 vector:insert ligation ratio. C) 1:3 vector:insert ligation ratio. D) Vector only control 
(1:0 ligation ratio). E) Bacteria only control. 
 
 
3.1.1.5 Restriction mapping 
Restriction mapping, using the HindIII restriction enzyme, was used to confirm the successful ligation 
of the mAb9.2.27(scFv) insert into the pCB-SNAP backbone. A virtual simulation was first performed 
on SnapGene in order to determine which enzyme would produce differential fragmentation of the 
original pCB-H22-SNAP plasmid compared to the novel pCB-CSPG4-SNAP plasmid (Figure 13A). The in 
vitro mapping confirms that fragmentation has occurred as expected (Figure 13B). This gives 
Sample  Yield (ng/μL) 
1 16.5   
2 14.2 
3 10.2 
Sample (vector:insert) Number of colonies Transformation efficiency Autoligated clone (%) 
1:1 904 2.2 x 106 1.22 
1:2 112 1.4 x 105 9.82 
1:3 208 1.7 x 105 5.29 
1:0 (vector only) 11 n/a 100 
0:0 (bacteria only) 0 n/a n/a 
D 
A C 
 
B 
E 
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confirmation that the correct fragments have been ligated and that autoligated clones have not been 
selected. 
 
Figure 13: Restriction mapping to confirm ligation of mAb9.2.27(scFv) insert into pCB-SNAP vector. A) In Silico agarose gel 
simulation using SnapGeneTM. A 1Kb DNA ladder (MW) was used to evaluate fragment sizes of pCB-H22-SNAP (lane 1) and 
pCB-CSPG4-SNAP (lane 2) when cut with HindIII. B) In vitro restriction mapping of pCB-H22-SNAP and pCB-CSPG4-SNAP with 
HindIII. A 1Kb DNA ladder and a 100 bp+ DNA ladder were used to evaluate fragment sizes (MW1 and MW2) of undigested 
pCB-H22-SNAP (lane 1), digested pCB-H22-SNAP (lane 2), undigested pCB-CSPG4-SNAP (lane 3) and digested pCB-CSPG4-
SNAP (lanes 4-6). MW: molecular weight. 
 
 
3.1.1.6 DNA sequencing 
Of the clones that were confirmed through restriction mapping, two were bulk prepped (Table 4.1), 
diluted to 20ng/μL in 30 μL, and sent for sequencing. The sequences of both clones were confirmed 
(see Appendix 6.2.1). 
 
Table 4.1: Quantification of pCB-CSPG4-SNAP recombinant clones, following large scale 
purification 
 
 
 
 
  
 
3.1.2 Transfection and protein expression 
Upon confirmation of its ORF sequence, the pCB-CSPG4-SNAP plasmid was introduced into a 
HEK293T mammalian vector expression system, co-expressing eGFP. Successful transfection 
Clone Yield (ng/uL) 260/280 260/230 
1 1728.4 1.92 2.26 
2 1817.0 1.83 2.02 
A     MW1  MW2       1           2          3          4           5           6  
3 kB 
1 kB 
500 bp 
B 
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and expression of the mAb9.2.27(scFv)-SNAP fusion protein was determined via visualization 
of eGFP reporter gene expression and zeocin was subsequently used to select for positively 
transfected cells, enriching this population (Figure 14). Transfection efficiency was evaluated 
visually by taking the average of multiple cell counts and was determined to be approximately 
63.3%. The cell culture supernatant (CCSN) containing secreted fusion protein was collected 
every 3-4 days over four weeks as described in section 2.1.2. 
 
Figure 14: Enhanced green fluorescent protein expression in HEK293T cells transfected with pCB-CSPG4-SNAP. A) 
Brightfield, B) green channel C) merge image. Scale bar: 100 µm 
 
 
3.1.3 Protein purification and analysis 
3.1.3.1 Protein purification 
mAb9.2.27(scFv)-SNAP fusion proteins were purified through a single-step purification using 
column immobilized nickel ions to which hexa-histidine-tag of mAb9.2.27(scFv)-SNAP had a 
strong affinity. Hence, elution of the recombinant protein was performed through 
competitive binding affinity between hexa-histidine-tag of mAb9.2.27(scFv)-SNAP and 
increased concentration of imidazole to Ni2+ on the column. Collection of the eluted fractions 
was monitored at wavelength 280 nm (Figure 15). The fractions (5mL) which corresponded 
to each individual peak on the chromatogram were then concentrated down to a volume of 
200 µL, using 10kDa Amicon Ultra-Filtration devices. The concentrated fractions were 
transferred onto a nitrocellulose membrane for immunodetection using an anti-His primary 
and HRP-conjugated secondary antibody and confirming expression of full-length protein. The 
first and largest peak, prior to the increase in the gradient of the elution buffer contains BSA 
flow through. The second peak, seen immediately after the imidazole gradient and spanning 
fractions 4-12, has several shoulders and was predicted to contain mAb9.2.27(scFv)-SNAP 
contaminated with BSA that bound non-specifically to the column and was eluted at the 
initiation of the elution buffer gradient. The third peak, spanning fractions 14-18, shows major 
irregularities in the absorbance reading. This was due to air bubbles entering the system. 
C B A 
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However, these fractions were tested for the presence of mAb9.2.27(scFv)-SNAP. The fourth 
peak, spanning fractions 23-25, was also suspected to contain mAb9.2.27(scFv)-SNAP. 
 
Figure 15: Chromatograph from IMAC purification of His6-tagged mAb9.2.27(scFv)-SNAP fusion proteins.  
 
 
3.1.3.2 Protein validation and quantification  
Following IMAC, fractions corresponding to the peaks above were run on an SDS-PAGE gel to 
identify the presence of protein corresponding to the weight of mAb9.2.27(scFv)-SNAP (53.13 
kDa) and determine which fractions should thus be pooled (Figure 16). Fractions 5-11 showed 
multiple bands, indicating the presence of mAb9.2.27(scFv)-SNAP and BSA contaminant. 
Fractions 12, 16, 17, 23-25 showed a single band each of an appropriate weight. These  were 
thus pooled (pool 1) during protein concentration. Fractions 6-11 (pool 2) were pooled and 
concentrated, with fraction 5 (pool 3) concentrated separately due to volume limitations. 
Based on the data generated on GelAnalyzer using raw volume values, the protein yield was 
estimated to be 27,59%. 
 
The concentration of the protein was then determined by measuring absorbance on a 
NanoDrop ND-2000, and these values were used to measure the volume of protein required 
for Western blot. The 260/280 ratio is 0.57 when protein is 100% pure and 1.06 when protein 
is 95% pure. All four samples are will within this range (Table 5.1).  
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Figure 16: SDS-PAGE with coomassie blue stain to detect presence of protein. A protein ladder (MW) was used to 
evaluate the molecular weight of the protein in each band. The numbers correspond to the fraction represented in the 
chromatogram. This was used to determine the contents of each fraction in order to determine appropriate fraction pools. 
 
 
 Table 5.1: Quantification of purified mAb9.2.27(scFv)-SNAP 
 
 
 
 
 
 
3.1.3.3 Protein confirmation 
Following quantification, functional His6-tag protein was detected by Western blot (Figure 17). 
An Anti-His6-tag antibody conjugated to HRP was used for the chemiluminescent detection of 
functional His6-tag protein. As predicted, pool 1 contain high quantities of mAb9.2.27(scFv)-
SNAP. Some functional protein was seen in pool 2, but none was detected in pool 3. Pool 1 
was thus used for downstream experiments. 
 
Figure 17: Visualization functional His6-tag protein.  A protein ladder (MW) was used to evaluate the molecular weight of 
the protein in each band. The numbers correspond to pools 1, 2 and 3. 
 
 
3.1.4 Immunoassays 
3.1.4.1 Flow cytometry 
Selective binding of mAb9.2.27(scFv)-SNAP-Alexa488 conjugates to CSPG4-positive 
melanoma cell lines was confirmed by flow cytometry. MDA-MB-468 was used as a negative 
control and SK-MEL-28 as a positive control. All additional cell lines, except for IGR-1, showed 
Pool Fractions Conc. (mg/mL) 260/280 Vol. loaded (μL) 
1 12,16,17,23-25 1.5645 0.68 1.278 
2 8-11 2.2120 0.57 0.904 
3 5 2.3295 0.61 0.859 
     MW            1                2                3   
50 kDa 
 MW        5             6            7          8           9        10          11           MW       12         16         17          23        24        25  
70 kDa 
55 kDa 
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significant binding relative to unlabelled control cells (Figure 18B-F), while the MDA-MB-468 
cells did not (Figure 18A). This is indicative of specific binding of the conjugate to cells 
expressing CSPG4. Furthermore, these results confirm that CSPG4 is over-expressed in 
melanoma cells in all growth stages, with and without pigmentation, and in it chemoresistant 
form. CSPG4 is thus been conclusively identified as a suitable target for melanoma in this and 
future PIT strategies. Table 7.1 shows the quantification of mean fluorescent intensity (MFI), 
here represented as the geometric mean (gMFI), for all cell lines when cells are unlabelled 
(background autofluorescence) compared to when they are labelled (signal). As is show, the 
gMFI of the control cell line remains unchanged, while the signal-to-background ratio of the 
CSPG4-positive cell lines is increased up to 14:1.  
 
Figure 18: Validation of binding of mAb9.2.27(scFv)-SNAP to CSPG4-positive melanoma cells by flow cytometry, where the 
x-axis represents the gMFI and the y-axis represents the number of events. A) MDA-MB-468 negative control. B) SK-MEL-
28 positive control. C) A375. D) WM902. E) UCT-Mel1. F) UCT-Mel1-DTIC. G) IGR-1. H) IGR-39 
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Table 6.1: Quantification of geometric mean fluorescence 
 
 
 
 
 
 
 
 
 
 
 
3.1.4.2 Confocal microscopy  
Confocal microscopy was performed to further validate binding of mAb9.2.27(scFv)-SNAP to 
the surface of the melanoma cells. As seen above, CSPG4-positive cell lines exposed to the 
conjugate all showed significant surface binding (Figure 19B-F), while the CSPG4-negative 
control did not (Figure 19A). It should be noted that the intensity of the signals does not 
correlate with the flow cytometry gMFI data above. This suggests that the cell lifting in flow 
cytometry affects the surface receptor expression of adherent cells. Nonetheless, these 
results confirm that mAb9.2.27(scFv)-SNAP is suitable for diagnostic imaging.  
Cell line Unlabelled Labelled 
MDA-MB-468 2.67 2.71 
SK-MEL-28 3.34 25.73 
A375 1.68 5.83 
WM902 1.52 19.06 
UCT-Mel1 1.93 19.63 
UCT-Mel1-DTIC 1.86 25.98 
IGR-1 2.23 4.38 
IGR-39 2.21 19.26 
A B 
C D
B 
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Figure 19: Confirmation of surface binding of mAb2.9.27(scFv)-SNAP to CSPG4-positive melanoma cells by confocal 
microscopy. A) MDA-MB-468 negative control. B) SK-MEL-28 positive control. White arrow: membrane signal; yellow arrow: 
cytoplasmic signal. C) A375. D) WM902. E) UCT-Mel1. F) UCT-Mel1-DTIC. G) IGR-1. H) IGR-39. I) Autofluorescence unstained 
control 
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3.1.5 Cell viability  
The XTT cell viability assay is dependent upon the cleavage of yellow tetrazolium salt by 
metabolically active cells to form orange formazan crystals, which absorb light at 450 nm. 
After administration of mAb9.2.27(scFv)-SNAP-IR700 and irradiation with 689 nm light, cells 
received 50 µL of XTT solution 1 and 1 µL of XTT solution 2. After 4 hours, absorbance was 
measured in order to determine the percentage of viable cells. Across all technical and 
biological repeats, no cytotoxicity was seen in any cell lines, i.e. no dose-dependent change 
in the absorbance reading. Figure 20 shows absorbance as a function of mAb9.2.27(scFv)-
SNAP-IR700 concentration for the negative and positive control cell lines, MDA-MB-468 and 
SK-MEL-28, respectively. Similar results were seen for other CSPG4-positive cell lines. Due to 
the absence of a dose-dependent response, IC50 curves were not generated. Given the 
convincing binding data, as illustrated through both flow cytometry and confocal microscopy, 
which furthermore confirms the preservation of the autocatalytic self-labelling reaction of 
SNAP-tag and its substrates, it can be concluded that the method used for solubilization of 
the lyophilized BG-IR700 was inefficient and lead to inadequate conjugation. 
 
Figure 20: XTT cell viability assay. Absorbance vs dose concentration curves showing activity of mAb9.2.27(scFv)-SNAP-
IR700 on SK-MEL-28 (positive control), MDA-MB-468 (negative control). Doses range from 0 to 1000 nM.  
A B 
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3.2 αPDL1(scFv)-SNAP-ALEXA488 FOR PD-L1 IMMUNODETECTION 
3.2.1 in silico cloning 
3.2.1.1 In silico vector design 
As per section 3.1.1.1, H22(scFv) was removed from the pCB-H22-SNAP backbone vector and 
replaced with the αPD-L1 scFv to create the pCB-PDL1-SNAP plasmid (Figure 21).  
 
 
 
B 
A 
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Figure 21: In silico design of pCB-PDL1-SNAP expression vector, containing αPD-L1(scFv) and SNAP-tag. A) Diagrammatic 
representation of the structure of the ORF. B) pCB-PDL1-SNAP plasmid map. D) Annotated protein sequence of ORF.  
 
 
3.2.1.2 Midiprep DNA isolation 
PUC57αPD-L1(scFv) plasmid was bulk prepped, transformed and purified, as per section 3.1.1.2 
(Table 7.1). The purified plasmid samples were all within the acceptable purity range and are 
thus confirmed for downstream application. 
 
Table 7.1: Quantification of pUC57αPD-L1(scFv) plasmid, following large-scale purification 
 
 
Sample Yield (ng/μL) 260/280 260/230 
1 4330.1 1.78 2.08 
2 138.3 1.82 2.00 
Sample Yield (μg/μL) 260/280 260/230 
1 1797.0  1.96 2.26 
2 465.1 1.83 2.02 
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3.2.1.3 Restriction enzyme digestion and agarose gel electrophoresis 
Digestion of the pUC57αPD-L1scFv) production vector was successful, with a small band seen at 
approximately 720 bp (Figure 22). 
 
Figure 22: RE digest of pUC57αPD-L1(scFv). Fragment sizes were evaluated using a 1kB DNA ladder (MW). An undigested control 
was used for comparison (lane 1) and pUC57αPD-L1(scFv) was digested with SfiI and NotI (lane 2).  
 
 
3.2.1.4 Gel extraction and ligation 
Insert bands were extracted from the gel and purified. Sample 2 of the vector, 51.5 ng/μL 
(Table 3.1) was ligated with the insert (42.6 ng/μL; Table 8.1).  
 
During ligation, three vector:insert ratios (1:2, 1:3 and 1:5) were used (Figure 23). The 1:3 
plate shows the highest transformation efficiency. Although transformation efficiency was 
low, the vector only control shows no colony formation of autoligated clones, thus selection 
of such a clone would be very unlikely. The bacteria only control has no colony formation, 
confirming that all colonies present contain the pCB-SNAP vector. Table 8.2 contains 
information regarding the colony formation of each plate.  
 
 
Table 8.1: Quantification of insert purified from agarose gel 
 
 
 
 
 
 
 
Sample  Yield (ng/μL) 
1 42.6   
2 16.4 
     MW               1               2 
3 kb 
1 kb 
500 bp 
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Table 8.2: Colony formation data 
 
 
Figure 23: Ligation of αPD-L1 insert into pCB-SNAP backbone to create final recombinant plasmid, pCB-PDL1-SNAP, and 
subsequent transformation of pCB-PD-L1-SNAP into E. coli. A) 1:2 vector:insert ligation ratio. B) 1:3 vector:insert ligation 
ratio. C) 1:5 vector:insert ligation ratio. D) Vector only control (1:0 ligation ratio).  
 
 
 
 
 
Sample 
(vector:insert) 
Number of colonies Transformation 
efficiency 
Autoligated clone (%) 
1:2 0 0 n/a 
1:3 68 2.1 x 104 0 
1:5 0 0 n/a 
1:0 (vector only) 0 n/a n/a 
0:0 (bacteria only) 0 n/a n/a 
A B 
C D
A 
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3.2.1.5 Restriction mapping 
Restriction mapping, using the BamHI restriction enzyme, was used to confirm the successful ligation 
of the αPD-L1(scFv) insert into the pCB-SNAP backbone. A virtual simulation was first performed as 
per section 3.1.1.5 (Figure 24A). The in vitro mapping shows the expected fragmentation, confirming 
correct ligation (Figure 24B).  
 
 
Figure 24: Restriction mapping to confirm correct ligation of αPD-L1(scFv) insert into pCB-SNAP vector. A) In Silico agarose 
gel simulation using SnapGeneTM. A 1Kb DNA ladder (MW) was used to evaluate fragment sizes of pCB-H22-SNAP (lane 1) 
and pCB-PDL1-SNAP (lane 2) when cut with BamHI. B) In vitro restriction mapping of pCB-H22-SNAP and pCB-PDL1-SNAP 
with BamHI. A 1Kb DNA ladder and a 100 bp+ DNA ladder were used to evaluate fragment sizes (MW1 and MW2) of digested 
pCB-H22-SNAP (lane 1) and digested pCB-PDL1-SNAP (lanes 2). 
 
 
3.2.1.6 DNA sequencing 
Of the clones that were confirmed through restriction mapping, two were bulk prepped (Table 10.1), 
diluted to 20ng/μL in 30 μL, and sent for sequencing. The sequences of both clones were confirmed 
(see Appendix 6.2.2) 
 
Table 9.1: Quantification of pCB-PDL1-SNAP recombinant clones, following large scale 
purification 
 
 
 
 
  
3.2.2 Transfection and protein expression  
Upon confirmation of its ORF sequence, the pCB-PDL1-SNAP plasmid was introduced into a 
HEK293T mammalian vector expression system, co-expressing eGFP. Successful transfection 
Clone Yield (ng/uL) 260/280 260/230 
1 1438.9 1.90 2.13 
2 959.8 1.92 2.14 
A B 
3 kB 
1 kB 
500 bp 
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and expression of the αPDL1(scFv)-SNAP fusion was determined via visualization of eGFP 
reporter gene expression and zeocin was used to select for positively transfected cells, 
enriching this population (Figure 25). Transfection efficiency was evaluated visually by taking 
the average of multiple cell counts and was determined to be approximately 52.3%. The cell 
culture supernatant (CCSN) containing secreted fusion protein was collected every 3-4 days 
over 4 weeks.  
 
Figure 25: eGFP expression in HEK293T cells transfected with pCB-PDL1-SNAP. A) Brightfield, B) green channel C) merge 
image. Scale bar: 100 µm 
 
3.2.3 Protein purification and analysis 
3.2.3.1 Protein purification 
CCSN harvests were enriched as per section 3.1.3.1. Figure 26 shows the resultant 
chromatograph. The first and largest peak has several shoulders. It was predicted that 
fractions 3-7 would contain mostly BSA that bound non-specifically to the column and was 
eluted at the initiation of the imidazole gradient. Fractions 8-18 were expected to contain 
αPDL1(scFv)-SNAP. The third peak, at fraction 23, was also suspected to contain αPDL1 (scFv)-
SNAP. 
Figure 26: Chromatograph from IMAC purification of His6-tagged αPDL1(scFv)-SNAP fusion proteins.  
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3.2.3.2 Protein validation and quantification  
Following IMAC, fractions corresponding to the peaks above were run on an SDS-PAGE gel to 
identify protein corresponding to the weight of αPDL1(scFv)-SNAP (52.03 kDa) and determine 
which fractions should be pooled (Figure 27). Fractions 5-7 showed multiple bands, indicating 
the presence of αPDL1(scFv)-SNAP and BSA contaminant. Fractions 8-15 showed a single band 
each of an appropriate weight. Fraction 23 had no visible band. Fractions 8-12 (pool 1) and 
13-15 (pool 2) were thus pooled and concentrated. Based on the data generated on 
GelAnalyzer, the protein yield was estimated to be 56.12%. 
 
The concentration of αPDL1(scFv)-SNAP was then determined and these values were used to 
measure the volume of protein required for Western blot. Protein purity was determined, 
with all four samples falling will within the acceptable purity range (Table 11.1).  
 
Figure 27: SDS-PAGE with coomassie blue stain to detect presence of protein. A protein ladder (MW) was used to evaluate 
the molecular weight of the protein in each band. The numbers correspond to the fraction represented in the chromatogram. 
This was used to determine the contents of each fraction in order to determine appropriate fraction pools. 
 
 
Table 10.1: Quantification of purified αPDL1(scFv)-SNAP 
 
 
 
 
 
 
3.2.3.3 Protein confirmation 
Following quantification, functional His6-tag protein was validated by Western blot (Figure 
28). An Anti-His6-tag antibody conjugated to HRP was used for the chemiluminescent 
detection of functional protein. As predicted, pool 1 contain high quantities of αPDL1(scFv)-
SNAP. Some was seen in pool 2, but no functional protein was detected in pool 3. Pool 1 was 
thus used for downstream experiments. 
 
Pool Fractions Conc. (mg/mL) 260/280 Vol. loaded (uL) 
1 8-12 1.2505 0.62 1.622 
2 13-15 1.2330 0.60 1.599 
MW       5         6          7         8         9       10      11     12       13           MW       14          15            
23 
70 kDa 
55 kDa 
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Figure 28: Visualization functional His6-tag protein.  A protein ladder (MW) was used to evaluate the molecular weight of 
the protein in each band. The numbers correspond to pools 1 and 2. 
 
 
3.2.4 Immunoassays 
3.2.4.1 Flow cytometry 
αPDL1(scFv)-SNAP-Alexa488 conjugates were used to label cells and 1) confirm functional 
binding of the fusion protein and 2) investigate the prevalence of PD-L1 expression across the 
various cell lines. A375 is reported to be PD-L1-positive(161) and was used as a positive control. 
However, no binding was seen on this cell line (Figure 29B). SK-MEL-28, WM902 and UCT-
MEL1 additionally showed no expression, and IGR-1 and IGR-39 show little expression (Figure 
29C-E). The PD-L1-positive triple negative breast cancer cell line, HS578T, was thus used to 
confirm functional binding (Figure 29A). However, HS578T showed little binding in this assay. 
It is unclear whether these negative results are due to dysfunction of the protein, e.g. protein 
misfolding, or due to alterations in cellular receptor expression, e.g. loss of receptors when 
lifting cells. Overall, both aims of this experiment remain inconclusive. Table 12.1 shows the 
quantification gMFI for all cell lines when cells are unlabelled (background) compared to when 
they are labelled (signal). As is show, there is little change in gMFI across samples, with signal-
to-background ratios of no higher than 2.76. 
 
Table 11.1: Quantification of geometric mean fluorescence 
 
 
 
 
 
 
 
 
 
 
Cell line Unlabelled Labelled 
HS578T 2.34 6.45 
A375 1.44 1.40 
SK-MEL-28 2.93 3.00 
WM902 1.80 1.96 
UCT-Mel1 1.97 1.91 
IGR-1 2.23 3.42 
IGR-39 2.21 3.65 
       MW        1             2               3 
50 kDa 
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Figure 29: Validation of binding of αPDL1(scFv)-SNAP to CSPG4-positive melanoma cells by flow cytometry, where the x-
axis represents the MFI and the y-axis represents the number of events. A) HS578T functional control. B) A375 positive 
control. C) SK-MEL-28. D) WM902. E) UCT-Mel1. F) IGR-1. G) IGR-39  
 
 
3.2.4.2 Confocal microscopy  
Confocal microscopy was performed to further investigate binding of αPDL1(scFv)-SNAP to 
cell surface PD-L1 in melanoma cells. Cells were labelled with αPDL1(scFv)-SNAP-549 for 
viewing. The staining patterns conformed to the data obtained by flow cytometry. 
Cytoplasmic staining was observed in some cell lines (Figure 30A-H), however; this is 
suspected to be noise, rather than true signal due to the fact that the gain used to collect 
these images was raised in an attempt to detect potentially weak signals. It is possible that 
expression was not changed due to lifting cells with trypsin but rather that prolonged culture 
A 
 
B C 
 
E D F 
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periods might be the cause of changes in receptor expression in the reportedly PD-L1-positive 
cell lines. More likely, there might be issues with the epitope-paratope interactions of this 
protein. 
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Figure 30: Confirmation of binding of αPDL1(scFv)-SNAP to melanoma cells by confocal microscopy. A) HS578T functional 
control. B) A375 positive control. Yellow arrow: cytoplasmic signal. C) SK-MEL-28. D) WM902. E) UCT-Mel1. F) IGR-1. G) IGR-
39. H) Autofluorescence unstained control 
 
 
3.2.5 Sequence generation 
Binding studies with the aPDL1(scFv)-SNAP construct developed in this study were 
inadequate. Given the lack of convincing evidence, it is concluded that this antibody is not 
binding to the desired antigen, perhaps due to problems in the sequence used. A new 
antibody must therefore be generated, using a sequence that has confirmed binding data. 
The sequence of the anti-PD-L1 antibody 3G10 was thus obtained from publication.(162) All 
FRs and CDRs were identified and CDRs were subsequently aligned with the sequence (Figure 
31). With the sequence confirmed, a pUC57 production vector containing the scFv was 
ordered for future work with this target. 
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Figure 31: 3G10 anti-PD-L1 antibody CDR alignment. A) VH CDR1. B) VH CDR2. C) VH CDR3. D) VL CDR1. E) VL CDR2. F) VL CDR3. 
 
  
C
B 
D
C
F
C
E
C
 68 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Figure 32: Summary figure. Step 1: in silico vector design using the pCB-SNAP mammalian expression vector. Step 2: 
molecular cloning of the mAb9.2.27(scFv) and PD-L1(scFv) inserts into the pCB-SNAP vector, confirmed through agarose gel 
electrophoresis. Step 3: successful transfection of ligated pCB- mAb9.2.27(scFv)-SNAP and PD-L1(scFv)-SNAP vectors into 
HEK293T cells, confirmed through eGFP expression. Step 4: purification of mAb9.2.27(scFv)-SNAP and PD-L1(scFv)-SNAP 
proteins, confirmed through SDS-PAGE and western blot analysis. Step 5: confirmation of binding of mAb9.2.27(scFv)-
IN	SILIICO	DESIGN MOLECULAR	CLONING 
TRANSFECTION
 
BINDING 
CYTOTOXICITY	 
         MW       1              2             3    
50 kDa 
PROTEIN	PURIFICATION/VALIDATION 
SK-MEL-28,	mAb9.2.27(scFv)-SNAP-Alexa488 
Results inconclusive. 
Troubleshooting to take place in 
future work 
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SNAP-Alexa488 and PD-L1(scFv)-SNAP-Alexa48 proteins, confirmed through flow cytometry and confocal microscopy. Step 
6: cytotoxicity of mAb9.2.27(scFv)-SNAP-IR700, confirmed through XXT assay. 
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4. Discussion 
4.1 Melanoma 
At present, the gold standard treatment for melanoma is surgical resection. However, while 
this strategy is effective at managing the disease when it is localized and in its early stages, 
those who are diagnosed at the late stages of the disease have very few options. According 
to the American Society of Clinical Oncology (2016), when patients are diagnosed early and 
undergo resection at the primary site the 5-year survival rate is 99%. If the cancer has invaded 
the lymph nodes 5-year survival rates drop to 63%. Once patients have reached the late 
metastatic stages survival rate drops further to 20%.(163) In South Africa, the unfortunate 
reality is that many patients present with late stage metastatic disease, as early diagnosis for 
is not always possible due to inadequate availability and access of diagnostic tools. (113) The 
low survival rates in late stage melanoma, as well as its inherent resistance to traditional 
chemotherapies and radiotherapies, have necessitated the need to develop alternative 
treatment strategies. These strategies include targeted therapies such as vemurafenib, which 
acts to inhibit mutated BRAF, and immunotherapies such as ipilimumab, which blocks the 
CTLA-4 immune checkpoint.(8, 9)  
 
4.2 Immunotherapy 
The ability to target cellular markers that are specific to various cancers has revolutionized 
our approach to treating this heterogenous disease. With so many phenotypical and 
genotypical differences between individual tumours (inter-tumour heterogeneity), and even 
between cell subpopulations within a single tumour (intra-tumour heterogeneity), it becomes 
necessary to consider that tumours with different morphologies, metabolisms, metastatic 
potentials and gene expression profiles might require different treatments. Heterogeneity 
affects drug resistance and patient outcome.(164, 165) So far, only thirteen mAbs have been FDA 
approved for use in cancer, three of which are used in detection only. Of the remaining ten, 
three are specific to melanoma. These are nivolumab and pembrolizumab, which target PD-
1, and ipilimumab, which targets CTLA-4.(9, 131, 132) In addition to these mAbs, while there are 
currently 175 ADCs under investigation, only four are FDA approved. These are brentuximab 
vedotin, which treats relapsed/refractory Hodgkin lymphoma by targeting CD30; ado-
trastuzumab entansine, which treats breast and lung cancer by targeting HER2; inotuzumab 
ozogamicin, which treats relapsed/refractory acute lymphoblastic leukemia by targeting 
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CD22; and gemtuzumab ozogamicin, which treats acute myeloid leukemia by targeting 
CD33.(166-170) While so much research is now being directed towards antibody-based therapies, 
the clinical approval rate is very low due to the limited efficacy of mAbs to induce cell death 
through inhibition of cell signalling, CDC or ADCC. (66, 75, 76) The success of mAbs is hindered by 
three problems: 1) they rely on the antibody-mediated response of a host immune system 
that is compromised and functioning sub-optimally, 2) they are working against cells that have 
developed advanced immune evasion mechanisms and are able to alter their 
microenvironment to induce immune tolerance, and 3) in response to repeated exposure to 
an mAb, cancer cells often adapt by downregulating the target receptor, thus causing 
resistance to the abrogated signal. (82, 171-173) It is for these reasons that ADCs have gained 
popularity.  
 
Traditional cancer therapies rely on free toxins to kill aberrantly dividing cells, but their non-
specificity contributes to systemic toxicity. Nausea, vomiting, hair loss, loss of appetite, 
decreased sexual life, dyspnoea, fatigue, pain and reduced ability to perform daily activities 
are just some of the side effects endured by patients on these toxic treatment regimes. Their 
overall quality of life is drastically reduced.(174, 175) By conjugating toxins to antibodies or 
antibody fragments, drugs are delivered directly to malignant cells with minimal or no effect 
on healthy cells. This specificity even allows for the use of drugs, such as Auristatin, that would 
otherwise be too toxic in the body. Furthermore, by using photosensitive compounds, the 
cytotoxic properties of the compound can be controlled through light activation. In the case 
that there is some anomalous off-target accumulation of the conjugate in tissues other than 
the tumour, it will have no effect at these sites, unless activated by light of a particular 
wavelength.(23) In addition to this, controlled drug release is provided by cleavable linkers.  
The polyethylene glycol (PEG) linker used here ensures that toxins are not released freely into 
the bloodstream but only detach from their antibodies once internalised into the target cells 
and exposed to the acidic environment of the endolysosome.(176, 177) Thus the 
photoimmunotherapy strategy used in the current study provides multiple levels of control 
to prevent unwanted cytotoxicity. 
 
In the engineering of ADCs, a heterogenous population is produced, in which the 
configuration and stoichiometry of the conjugates is varied. This is a significant shortcoming 
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that negatively affects the probes’ serum stability, creates challenges regarding their 
pharmacokinetics, and increases their risk of inducing immunogenicity. (11, 81, 87, 88, 178) The 
recombinant SNAP-tag scFv fusion proteins produced here have the advantages of 1) being a 
homogenous species with a 1:1 coupling at distinct site, 2) having a reduced size (±48-50 kDa), 
and thus increased tissue penetration compared to naked mAbs or ADCs, and 3) conferring 
minimal risk of induced immune response due to the human origin of the O6-alkylguanine-
DNA alkyltransferase enzyme from which SNAP-tag is engineered.  
 
4.2.1 Chondroitin sulphate proteoglycan as target for melanoma 
CSPG4 was first identified in melanoma and is known to be over-expressed in over 70% of 
primary tumour. It exhibits minimal expression in normal adult tissue but is highly expressed 
during foetal development.(134, 141-145)  In this stage of life, cell motility is at its highest, as 
tissues undergo major reorganisation.(179, 180) CSPG4 expression has also been observed on 
pluripotent stem cell, as well as on CSCs. (133, 147-149) It has been suggested that CSPG4 plays an 
integral role in the motility and organisation of these cells. CSPG4 has furthermore been 
implicated in various stages of cancer, from its role in initiation to its role in metastasis. (139-
142) Finally, CSPG4 expression has been identified in the pericytes and has shown to contribute 
to neoangiogenesis.(181) Pericytes are found within the basement membrane of the capillaries, 
where they play a crucial role in regulating proliferation of endothelial cells and subsequent 
growth of new capillaries.(182, 183) 
 
CSPG4 has been identified as a tumour rejection antigen in a study showing that over 50% of 
mice immunized with a fragment of the antigen saw complete elimination of melanoma 
xenografts within 56 days.(181) Moreover, in another study, 60% of melanoma patients that 
underwent CSPG4 immunization exhibited prolonged survival and regression of 
metastases.(184) Preclinical studies have shown that xenograft bearing mice treated with an 
anti-CSPG4 full-length mAb have significantly reduced tumour growth, increased survival and 
inhibited metastasis. Additionally, mAb targeting of CSPG4 appears to decrease 
neoangiogenesis, with mice treated with anti-CSPG4 mAb having decreased vessel density in 
the tumour vasculature.(133)  
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In the current study, it has been shown through significant binding analysis that CSPG4 is a 
suitable target for the targeting of melanoma. Selective binding of fluorescently labelled 
mAb9.2.27(scFv)-SNAP to CSPG4-positive melanoma cells was validated by flow cytometry 
and confocal microscopy. These data strongly support CSPG4 as a target for melanoma. Using 
seven melanoma cell lines that are differentially representative of the various forms of the 
disease, it can be concluded that CSPG4 is expressed during all three growth phases of 
melanoma, in both its pigmented and unpigmented forms, and in chemoresistant cells. This 
data aligns with reports regarding the involvement of CSPG4 in various cellular functions 
relating to proliferation (radial growth phase); invasion (vertical growth phase) and migration 
and angiogenesis (metastatic growth phase.)(1) 
 
 
4.2.2 Programmed death-ligand 1 as a target for melanoma 
The immune system is heavily compromised in cancer. Not only do cancerous cells develop 
advance mechanisms to avoid recognition by the T cells but activated T cells are frequently 
inactivated through immune checkpoints occurring via the CTLA-4 and PD-1/PD-L1 pathways. 
This allows for more aggressive tumour growth with decreased immune surveillance in the 
subset of patients overexpressing PD-L1.(70, 185-187) Pembrolizumab, which targets PD-1, has 
shown to be more effective in hindering melanoma tumour growth and increasing survival 
than its predecessor, ipilimumab, which targets CTLA-4.(131)  
 
In this study, PD-L1 targeting was inconclusive. While SDS-PAGE, GelAnalyzer and western 
blot indicate that functional His6-tagged fusion protein was successfully expressed and 
purified, no clear binding was seen on any of the melanoma cell lines, including the melanoma 
A375 and the breast cancer HS578T positive control cell lines. Due to delayed delivery of the 
commercial anti-PD-L1 antibody, which was to serve as a positive control, it remains 
unconfirmed whether this was due to altered receptor expression in the cells or due to a 
problem with the binding ability of the protein. However, it is expected that the latter is the 
likely case and that the sequence originally provided for the antibody contained errors. 
Consequently, in silico sequence generation was performed in order to reclone this protein 
using a new sequence obtained from publication. 
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4.3 SNAP-tag as a therapeutic tool 
4.3.1 Production of SNAP-tag fusion protein conjugates 
In this study, SNAP-tag technology was investigated for is ability to produce homogeneous 
conjugate preparations by providing a distinct binding moiety for the coupling of the self-
labelling enzyme with BG-modified substrates. Recombinant protein was engineered through 
the genetic fusion of the SNAP-tag cassette with the coding sequence of the anti-CSPG4 and 
anti-PD-L1 scFv. Endowed with SNAP-tag, any antibody can be autocatalytically labelled with 
any substrate that has been modified with a BG. 
 
In silico cloning of the scFv-SNAP construct produced an in-frame sequence, free of any stop 
codons that would interfere with the transcription of the DNA. The resultant sequence was 
thus used to generate the relevant insert (ordered from Genscript). Molecular cloning was 
performed to extract the insert and ligate it into the pCB-SNAP backbone. Visualisation of the 
agarose gels confirmed the success of the restriction enzyme digests used during this process. 
The presence of bacterial colonies on LB agar plates, together with the absence of colonies 
on the bacteria only and vector only control plates, indicated the success of the ligation step, 
indicating 1) that all colonies contained the pCB-SNAP vector and 2) there was a very low rate 
of autoligation, making it unlikely to select an autoligated clone for downstream studies. This 
was further confirmed through restriction mapping, which demonstrated differential 
fragmentation of the ligated clones compared to the original vector. The final step in the 
cloning process was to confirm the validity of the plasmid through DNA sequencing. In silico 
alignment was performed using the sequence generated in SnapGene and the data showed 
no missense, nonsense or frameshift mutations.  
 
After cloning, the vector was transfected in to HEK293T cells and expression was confirmed 
through visualization of GFP reporter gene expression. HEK293T cells allow for rapid 
expression and screening of recombinant proteins, and produce sufficiently a high yield for 
preclinical in vitro models (~5-15mg/L).(96, 188) Zeocin was used to select for positively 
transfected cells. Purification of the remaining supernatant was performed using IMAC, 
whereby SNAP fusion proteins were captured by their His6-tag. SDS-PAGE and GelAnalyzer 
were used to confirm the presence of protein corresponding to the size of the construct and 
determine the yield, and Western blot was then used to confirm functional His6-tag protein. 
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These protein validation assays further confirmed that the antigen binding of 
mAb9.2.27(scFv)-SNAP and the self-labelling activity of SNAP-tag were retained. Retention of 
the binding activity of the mAb9.2.27 scFv against CSPG4 is possible because SNAP-tag 
technology provides a distant conjugation, away from the paratope. By creating a spacer 
between the antibody and the effector molecule, the negative effects often associated with 
direct conjugation are avoided, such as altered structure, function and binding affinity. 
Moreover, functionality of the effector molecule, Alexa FluorTM 488, was preserved in the 
conjugation process. 
 
4.3.2 Targeted delivery of IR700 to tumour cells by SNAP-tag fusion protein 
Currently, several photosensitizers, such as Photofrin  and ALA, have been approved for 
clinical use, while others, such as Fotolon, have been approved for clinical trials.(189, 190) Unlike 
traditional cancer therapies, the cytotoxic effects of PDT are limited by their activation with 
harmless light. This has the advantage of significantly reducing systemic effects, such as 
necrosis of healthy tissue and photosensitivity. In the form of an antibody conjugate, these 
off-target effects are reduced even further compared to traditional PDT. This further allows 
for repeated treatment cycles, which facilitates tumour remission and decreases the risk of 
sub-curative treatment.(65, 66)  
 
The photosensitizer used here, IR700, was chosen because it has maximal excitation in the 
NIR range. This offers an optimal balance between tissue penetration and photon efficiency, 
with 17-fold increase in the extinction coefficient of IR700 compared to hypericin.(52, 53, 191) In 
a clinical setting, deeper tissue penetration becomes imperative. IR700 modified with a BG-
PEG24-NH2 linker was incubated at a 2-fold molar excess with mAb9.2.27(scFv)-SNAP. The 
conjugate was administered to previously mentioned cell lines and assessed for its ability to 
selectively kill those expressing CSPG4. These experiments were unfortunately unsuccessful. 
No phototoxicity was observed in the XTT cell viability assays. In light of the convincing binding 
analysis, it is concluded that inefficient solubilization of the lyophilized product resulted in 
inadequate conjugation of BG-IR700 with SNAP-tag. We were unable to confirm the 
conjugation of BG-IR700 to the fusion protein due to unavailability of an appropriate device 
able to detect the probe in the correct wavelength, i.e. 689 nm excitation and 700 nm 
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emission. None of the equipment available to us, the confocal microscope, flow cytometer 
and gel doc, had the appropriate filters for this purpose. 
 
4.4 Outlook and future work 
This study provides sufficient proof of concept for the use of CSPG4-specific SNAP-tag fusion 
protein in the selective targeting of melanoma. While several SNAP-tag fusion proteins have 
been developed to target other receptors, particularly EGFR, and other cancers, particularly 
breast cancer,(58, 108, 109, 192) no literature exists describing the use of this technology to target 
the CSPG4 antigen in melanoma. In existing in vivo studies, CSPG4-specifc SNAP-tag 
photoimmunoconjugates have not been investigated. Thus, once the issues encountered in 
this project, such as the unsuccessful conjugation of the BG-IR700 payload to the 
mAb9.2.27(scFv)-SNAP fusion protein, have been resolved, the logical continuation of this 
work is to progress with xenograft mouse models to evaluate the safety, biodistribution and 
biological activity of mAb9.2.27(scFv)-SNAP-IR700 as a novel cancer theranostic. Previous 
studies using anti-EGFR-SNAP recombinant proteins have shown that the protein exhibits high 
tumour accumulation and retention with simultaneous rapid renal filtration of unbound 
probe, creating a high tumour-to-background ratio 10 hours after administration of the 
probe,(57) allowing for efficient tumour imaging and minimizing the chance of off-target 
effects upon irradiation. In addition to its prominence in melanoma, CSPG4 is known to be 
overexpressed in several other cancers, including triple negative breast cancer and 
glioblastoma.(108, 135, 193) This photoimmunoconjugate might thus have potential use in the 
study, detect and treatment of these cancers.  
 
One potential alteration that might be made to the photoimmunoconjugate is to increase the 
valency, i.e. increase the DAR in order to increase the phototoxicity. A second consideration 
is the routing of the probe. While free PSs tend to accumulate in different organelle within 
the cell, such as the melanosomes, mitochondria, golgi apparatus and endoplasmic reticulum, 
depending on their specific chemistry,(3, 194, 195) antibody conjugates such as those developed 
in this study, are internalised by receptor-mediated endocytosis. This manner of routing 
directs the antibody, carrying its payload, to the endosomes. Understanding the exact routing 
of the conjugate becomes critical for future work aimed at clinical application as it informs us 
where the drug is being delivered and hence how it will take effect. It also informs us which 
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linkers to use to ensure suitable drug release. Internalisation by receptor-mediated 
endocytosis also indicates that there will be no non-specific internalisation of unconjugated 
drug.(151, 196, 197) Receptor-mediated endocytosis, which here is the assumed method of 
internalisation, routes the antibody and its payload into the early endosome, which matures 
into late endosome, and, finally, fuses with the lysosome, where it undergoes lysosomal 
degradation.(151) There is, however, a risk of damaging and decreasing the efficiency of the 
effector molecule. Thus, the use of the lysine-aspartic acid-glutamic acid-leucine (KDEL) 
sequence should be considered. This sequence routes any protein containing this sequence 
at its C terminal to the endoplasmic reticulum.(198, 199) Alternatively, endosomal escape 
strategies that create pores in the endosome for the release of cargo could be considered. 
One example is photochemical internalisation, a technique in which an amphiphilic 
photosensitizer is co-administered and localises within the endosomal membrane. Upon light 
activation, the production of ROS causes local disruption to the membrane, allowing for the 
release of the cargo into the cytosol. Other techniques utilize pH buffering systems, peptides, 
viruses, bacteria or chemicals to facilitate pore formation.(200, 201) 
 
In summary, we have been able to generate a next generation photoimmunotheranostic 
antibody fusion protein able to overcome several problems associated with traditional ADCs. 
Through the use of SNAP-tag technology, using a simple autocatalytic reaction that allows for 
a single step conjugation, we have produced a homogenous conjugate that shows retained 
function of both the mAb.9.2.27 scFv and the effector molecule. Efficient binding and dose 
dependent cytotoxicity are indicative of the future potential of this product in cancer therapy. 
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6.3 ABBREVIATIONS 
 
1O2   Singlet oxygen 
αCSPG4   Anti-CSPG4 
ABC transporter  ATP-Binding Cassette Transporter Protein 
ADC   Antibody-Drug Conjugate 
ADCC   Antibody-Dependent Cellular Cytotoxicity  
Alexa488  Alexa FluorTM 488 
AMP   Ampicillin 
AMPR   Ampicillin Resistance  
APC   Antibody-Photoabsorber Conjugate 
BG    Benzylguanine 
BRAF   Proto-oncogene B-Raf 
CANSA   Cancer Association of South Africa 
CAP   Catabolite Activator Protein 
CCSN   Cell Culture Supernatant 
CDC   Complement-Dependent Cytotoxicity 
Ce6   Chlorin e6 
CSC   Cancer Stem Cell 
CSPG4   Chondroitin Sulphate Proteoglycan 4 
CTL    Cytotoxic T Lymphocytes   
Cys145   Cysteine Residue 145 
DAR   Drug-to-Antibody Ratio 
DMEM   Dulbecco’s Modified Eagle’s Medium 
DMSO   Dimethyl Sulphoxide  
DTHe   Dimethyl Tetrahydroxyhelianthrone  
E. coli   Escherichia coli 
eGFP   Enhanced Green Fluorescent Protein 
EKR   Extracellular Signal-Regulating Kinase 
EMT   Epithelial-to-Mesenchyal Transition 
ER   Oestrogen Receptor 
FACS   Fluorescence-Activated Cell Sorting 
FAK   Focal Adhesion Kinase 
FBS   Foetal Bovine Serum 
Fc   Fragment Crystallizable 
FDA   United States Food and Drug Administration 
FRET   Fluorescence Resonance Energy Transfer 
GFP   Green Fluorescent Protein 
gMFI   Geometric Mean Fluorescent Intensity 
hAGT   Human Alkylguanine-DNA Alkyltransferase 
HER2   Human Epidermal Growth Factor Receptor 2 
HMW MAA  High Molecular Weight Melanoma-Associated Antigen 
HRP   Horse Radish Peroxidase 
IMAC   Immobilized Metal Affinity Chromatography 
LB   Luria Bertani Broth 
mAb   Monoclonal Antibody 
MAP-K    Mitogen-Activated Protein Kinase 
MBI   Medical Biotechnology and Immunotherapy Research Group 
MCSP   Melanoma-Associated Chondroitin-Sulphate Proteoglycan 
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MFI   Mean Fluorescent Intensity 
nfH20   Nuclease-Free (Molecule Biology Grade) Water 
NIR   Near Infrared Radiation 
ORF   Open Reading Frame 
PBS   Phosphate  
PD-1   Programmed Death Protein 1 
PD-L1   Programmed Death Ligand 1  
PDT   Photodynamic Therapy 
PIT   Photoimmunotheranostic 
PR   Progesterone Receptor 
PS   Photosensitizer 
RE   Restriction Enzyme 
RGP   Radial Growth Phase 
ROS   Reactive Oxygen Species 
sdH2O   Sterile Deionized (Molecular Biology Grade) Water 
SDS   Sodium Dodecylsulphate  
SDS-PAGE  Sodium Dodecylsulphate Polyacrylamide Gel Electrophoresis 
scFv   Single Chain Variable Fragment 
SOC   Super Optimal Broth with Catabolite repression 
TAA   Tumour-Associated Antigen 
T cell   T-Lymphocyte Cell 
TCR   T Cell Receptor 
TIL   tumour infiltrating lymphocytes  
TNBC   Triple Negative Breast Cancer 
TSA   Tumour-Specific Antigen 
UVR   Ultraviolet Radiation 
VEGF   Vascular Epithelial Growth Factor 
VGP   Vertical Growth Phase 
w/v   Weight per Volume 
XXT   Tetrazolium Dye Cell Proliferation Assay 
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6.4 Recipes 
6.4.1 1.2% (w/v) Agarose Gel Preparation 
Recipe (100mL) 
1.2g agarose powder 
Top up to 100mL 1X TAE Buffer 
10μL SYBRsafe 
 
Protocol 
1. Weigh agarose into a flask 
2. Top up to 100mL with 1X TAE Buffer 
3. Microwave at top voltage for 45 seconds (or until bubbles are seen) 
4. Allow to cool to touching temperature 
5. Add SYBRsafe 
6. Place comb and pour gel into tray 
7. Allow to set in a dark space (SYBRsafe is degraded by UV light) 
8. Once solidified, carefully remove comb 
9. Place in tank, fully submerged in 1X TAE Buffer 
10. Load samples with pipette as required 
 
 
6.4.2 Gel Electrophoresis  
 
4x Laemmli Loading Dye (5mL) 
0.151375g Tris (pH6.8) 
0.3g SDS 
0.00025g Bromophenol Blue 
2mL Glycerol 
0.5ml β-mercaptoethanol 
 
1M Tris (1L) 
121.1g Tris 
Top up to 800mL with dH2O 
Adjust to appropriate pH with HCl and NaOH 
Top up to 1000mL with dH2O 
 
5M NaOH (100mL) 
20g NaOH  
Top up to 100mL with dH2O 
 
5M HCl (100mL) 
8.239g HCl 
Top up to 100mL with dH2O 
 
0.5M EDTA (1L) 
146.12g EDTA pH8.0 (1L) 
Top up to 1000mL with dH2O 
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10X TAE (1L) 
48.4g Trizma Base 
20mL 0.5M EDTA pH8.0 
11.44mL glacial acetic acid 
Top up to 1000mL with dH2O 
 
1X TAE (1L) 
100mL 10X TAE 
900mL dH2O 
 
10X TE Buffer (1L) 
100mL 1M Tris-HCl pH7.5 
20mL 0.5M EDTA 
880mL dH2O 
 
 
6.4.3 LB Agar Plate Preparation 
 
Recipe (1L) 
35g LB agar powder (Sigma) 
Top up to 1000mL with dH2O 
Add AMP to 200ng/μl (stock at 100μg/ml) 
 
Protocol 
1. Place 35g LB agar powder in a flask 
2. Top up to 1L with dH20, stir to dissolve 
3. Autoclave for 15min at 121oC 
4. Cool to ~50oC (to be able to touch, but not to solidify) 
5. Pour negative plates 
6. Add AMP at correct ratio (e.g. 100μL AMP per 50mL LB) 
7. Pour plates 
8. Allow plates to cool and solidify 
 
 
6.4.4 Purification buffers 
 
 
 
  
 
 
 
 
 
 
 
4x Incubation buffer (pH 8.0) 
 
  
 Conc. Mr Mass(g) 
NaH2PO4 200mM 119.98 24.00 
NaCl 1.2M 58.44 70.13 
Imidazole 40mM 68.08 2.72 
ddH2O   fill to 1000ml 
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Equilibration buffer (pH 8.0) 
   
 Conc. Mr Mass(g) 
NaH2PO4 50mM 119.98 6.00 
NaCl 300mM 58.44 17.53 
ddH2O   fill to 1000ml 
Elution buffer (pH 8.0) 
   
 Conc. Mr Mass(g) 
NaH2PO4 50mM 119.98 6.00 
NaCl 300mM 58.44 17.53 
Imidazole 250mM 68.08 17.02 
ddH2O   fill to 1000ml 
